Journal articles on the topic 'RL-37'
To see the other types of publications on this topic, follow the link: RL-37.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'RL-37.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Zhao, Chengquan, Tung Nguyen, Lee Ming Boo, Teresa Hong, Cesar Espiritu, Dmitri Orlov, Wei Wang, Alan Waring, and Robert I. Lehrer. "RL-37, an Alpha-Helical Antimicrobial Peptide of the Rhesus Monkey." Antimicrobial Agents and Chemotherapy 45, no. 10 (October 1, 2001): 2695–702. http://dx.doi.org/10.1128/aac.45.10.2695-2702.2001.
Full textAbstract:
ABSTRACT Rhesus monkey bone marrow expresses a cathelicidin whose C-terminal domain comprises a 37-residue alpha-helical peptide (RL-37) that resembles human LL-37. Like its human counterpart, RL-37 rapidly permeabilized the membranes of Escherichia coli ML-35p and lysed liposomes that simulated bacterial membranes. When tested in media whose NaCl concentrations approximated those of extracellular fluids, RL-37 was considerably more active than LL-37 against staphylococci. Whereas human LL-37 contains five acidic residues and has a net charge of +6, rhesus RL-37 has only two acidic residues and a net charge of +8. Speculating that the multiple acidic residues of human LL-37 reduced its efficacy against staphylococci, we made a peptide (LL-37 pentamide) in which each aspartic acid of LL-37 was replaced by an asparagine and each glutamic acid was replaced by a glutamine. LL-37 pentamide's antistaphylococcal activity was substantially greater than that of LL-37. Thus, although the precursor of LL-37 is induced in human skin keratinocytes by injury or inflammation, its insufficiently cationic antimicrobial domain may contribute to the success of staphylococci in colonizing and infecting human skin.
2
Morgera, Francesca, Lisa Vaccari, Nikolinka Antcheva, Denis Scaini, Sabrina Pacor, and Alessandro Tossi. "Primate cathelicidin orthologues display different structures and membrane interactions." Biochemical Journal 417, no. 3 (January 16, 2009): 727–35. http://dx.doi.org/10.1042/bj20081726.
Full textAbstract:
The human cathelicidin LL-37 displays both direct antibacterial activities and the capacity to modulate host-cell activities. These depend on structural characteristics that are subject to positive selection for variation, as observed in a previous analysis of the CAMP gene (encoding LL-37) in primates. The altered balance between cationic and anionic residues in different primate orthologues affects intramolecular salt-bridging and influences the stability of the helical conformation and tendency to aggregate in solution of the peptide. In the present study, we have analysed the effects of these structural variations on membrane interactions for human LL-37, rhesus RL-37 and orang-utan LL-37, using several complementary biophysical and biochemical methods. CD and ATR (attenuated total reflection)-FTIR (Fourier-transform IR) spectroscopy on model membranes indicate that RL-37, which is monomeric and unstructured in bulk solution [F-form (free form)], and human LL-37, which is partly structured and probably aggregated [A-form (aggregated form)], bind biological membranes in different manners. RL-37 may insert more deeply into the lipid bilayer than LL-37, which remains aggregated. AFM (atomic force microscopy) performed on the same supported bilayer as used for ATR-FTIR measurements suggests a carpet-like mode of permeabilization for RL37 and formation of more defined worm-holes for LL-37. Comparison of data from the biological activity on bacterial cells with permeabilization of model membranes indicates that the structure/aggregation state also affects the trajectory of the peptides from bulk solution through the outer cell-wall layers to the membrane. The results of the present study suggest that F-form cathelicidin orthologues may have evolved to have primarily a direct antimicrobial defensive capacity, whereas the A-forms have somewhat sacrificed this to gain host-cell modulating functions.
3
Line, John Eric, Bruce S. Seal, and Johnna K. Garrish. "Selected Antimicrobial Peptides Inhibit In Vitro Growth of Campylobacter spp." Applied Microbiology 2, no. 4 (September 21, 2022): 688–700. http://dx.doi.org/10.3390/applmicrobiol2040053.
Full textAbstract:
Campylobacter is a major cause of acute human diarrheal illness. Broiler chickens constitute a primary reservoir for C. jejuni leading to human infection. Consequently, there is a need for developing novel intervention methods. Antimicrobial peptides (AMP) are small proteins which have evolved in most lifeforms to provide defense against microbial infections. To date, over 3000 AMP have been discovered; however, few of them have been analyzed specifically for ability to kill campylobacters. We selected and evaluated a set of 11 unique chemically synthesized AMP for ability to inhibit growth of C. jejuni. Six of the AMP we tested produced zones of inhibition on lawns of C. jejuni. These AMP included: NRC-13, RL-37, Temporin L, Cecropin–Magainin, Dermaseptin, and C12K-2β12. In addition, MIC were determined for Cecropin–Magainin, RL-37 and C12K-2β12 against 15 isolates of Campylobacter representing the three most common pathogenic strains. MIC for campylobacters were approximately 3.1 µg/mL for AMP RL-37 and C12K-2β12. MIC were slightly higher for the Cecropin–Magainin AMP in the range of 12.5 to 100 µg/mL. These AMP are attractive subjects for future study and potential in vivo delivery to poultry to reduce Campylobacter spp. populations.
4
Kazarov, Rafajel L., Pavel V. Maslov, Andrej V. Vasilev, Andrey V. Atanov, and Vladislav Ya Dubinskiy. "Multiple aneurysms of segmentary branches of renal arteries." Urologicheskie vedomosti 7, no. 2 (June 15, 2017): 34–37. http://dx.doi.org/10.17816/uroved7234-37.
Full textAbstract:
A clinical case of the presence of multiple aneurysms of segmental branches of the renal artery with a rupture of one of the aneurysms with the formation of a retroperitoneal hematoma. (For citation: Kazarov RL, Maslov PV, Vasilyev AV, et al. Multiple aneurysms of segmentary branches of renal arteries. Urologicheskie vedomosti. 2017;7(2):34-37. doi: 10.17816/uroved7234-37).
5
Shi, Yu, Lei Liu, Fei Hu, Guangqiang Fan, and Juntao Huo. "Nocturnal Boundary Layer Evolution and Its Impacts on the Vertical Distributions of Pollutant Particulate Matter." Atmosphere 12, no. 5 (May 7, 2021): 610. http://dx.doi.org/10.3390/atmos12050610.
Full textAbstract:
To investigate the evolution of the nocturnal boundary layer (NBL) and its impacts on the vertical distributions of pollutant particulates, a combination of in situ observations from a large tethered balloon, remote sensing instruments (aerosol lidar and Doppler wind lidar) and an atmospheric environment-monitoring vehicle were utilized. The observation site was approximately 100 km southwest of Beijing, the capital of China. Results show that a considerable proportion of pollutant particulates were still suspended in the residual layer (RL) (e.g., the nitrate concentration reached 30 μg m−3) after sunset. The NBL height calculated by the aerosol lidar was closer to the top of the RL before midnight because of the pollutants stored aloft in the RL and the shallow surface inversion layer; after midnight, the NBL height was more consistent with the top of the surface inversion layer. As the convective mixing layer gradually became established after sunrise the following day, the pollutants stored in the nocturnal RL of the preceding night were entrained downward into the mixing layer. The early morning PM2.5 concentration near 700 m in the RL on 20 December decreased by 83% compared with the concentration at 13:34 on 20 December at the same height. The nitrate concentration also decreased significantly in the RL, and the mixing down of nitrate from the RL could contribute about 37% to the nitrate in the mixing layer. Turbulence activities still existed in the RL with the bulk Richardson number (Rb) below the threshold value. The corresponding increase in PM2.5 was likely to be correlated with the weak turbulence in the RL in the early morning.
6
Berdaus, S. V. "DEVELOPING THE CONCEPT OF INTENTIONALITY IN THE DISCOURSE OF MODERN PSYCHOLOGY." Respublica literaria, RL.2022. Vol.3. No.1 (March 30, 2022): 28–37. http://dx.doi.org/10.47850/rl.2022.3.1.28-37.
Full textAbstract:
The main problematic background of the article is the nature, prospects and obligations associated with the borrowing of philosophical concepts and ideas by psychology. Reasons are expressed for introductory interventions in psychology from the side of philosophy. An exemplification of such an intervention is presented in the form of an analysis of psychological approaches to the interpretation of E. Husserl's concept of intentionality. R. May's interpretation of intentionality is considered in more detail. It is suggested that his version of the concept of intentionality uses the implicit connotations of the phenomenological interpretation of intentionality with Freud's theory of drive.
7
Berdaus, S. V. "DEVELOPING THE CONCEPT OF INTENTIONALITY IN THE DISCOURSE OF MODERN PSYCHOLOGY." Respublica literaria, RL.2022. Vol.3. No.1 (March 30, 2022): 28–37. http://dx.doi.org/10.47850/rl.2022.3.1.28-37.
Full textAbstract:
The main problematic background of the article is the nature, prospects and obligations associated with the borrowing of philosophical concepts and ideas by psychology. Reasons are expressed for introductory interventions in psychology from the side of philosophy. An exemplification of such an intervention is presented in the form of an analysis of psychological approaches to the interpretation of E. Husserl's concept of intentionality. R. May's interpretation of intentionality is considered in more detail. It is suggested that his version of the concept of intentionality uses the implicit connotations of the phenomenological interpretation of intentionality with Freud's theory of drive.
8
Wang, Mingcheng, Kelly A. Balmes, Tyler J. Thorsen, Dylan Willick, and Qiang Fu. "An Investigation of the Ice Cloud Detection Sensitivity of Cloud Radars Using the Raman Lidar at the ARM SGP Site." Remote Sensing 14, no. 14 (July 19, 2022): 3466. http://dx.doi.org/10.3390/rs14143466.
Full textAbstract:
The ice cloud detection sensitivity of the millimeter cloud radar (MMCR) and the Ka-band Zenith radar (KAZR) is investigated using a collocated Raman lidar (RL) at the Atmospheric Radiation Measurement Program Southern Great Plains site. Only profiles that are transparent to the RL with ice clouds only are considered in this study. The MMCR underestimates the RL ice cloud optical depth (COD) by 20%. The MMCR detects no ice clouds in 37% of the profiles. These profiles where ice cloud goes undetected by the MMCR typically contain very optically thin clouds, with a mean RL ice COD of 0.03. Higher ice cloud detection sensitivity is found for the KAZR, which underestimates the RL ice COD by 15%. The decrease in the ice COD bias for the KAZR compared to the MMCR is largely due to a decrease in the ice COD bias for the situation where the transparent profiles with ice clouds are detected by both the RL and cloud radar. The climatic net ice cloud radiative effects (CREs) from the RL at the top of the atmosphere (TOA) and the surface are 3.2 W m−2 and −0.6 W m−2, respectively. The ice CREs at the TOA and surface are underestimated for the MMCR by 0.7 W m−2 and 0.16 W m−2 (21% and 29%) and underestimated for the KAZR by 0.6 W m−2 and 0.14 W m−2 (17% and 24%). The ice clouds undetected by the cloud radars led to underestimating the climatic net cloud heating rates below 150 hPa by about 0–0.04 K day−1.
9
Ali, M. Saad, Hamna Naveed, Muhammad Ali Babar Abbasi, Nosherwan Shoaib, and Vincent F. Fusco. "Substrate-Integrated Coaxial Line (SICL) Rotman Lens Beamformer for 5G/B5G Applications." Electronics 12, no. 1 (December 24, 2022): 69. http://dx.doi.org/10.3390/electronics12010069.
Full textAbstract:
High-band allocations in the millimeter-wave (mm-Wave) frequency spectrum offer high-capacity wireless information transmission as required by fifth generation (5G) communication standards. Among different beamforming structures, the Rotman lens (RL) is an attractive passive-microwave-lens-based beamforming network due to its low fabrication cost, reliability, design simplicity and wide-angle scanning capabilities. Conventionally, the RL is implemented using microstrip line (MSL) technology for which there are inherent radiation losses that become severe when operating in mm-Wave 5G frequency bands. In this context, a novel substrate-integrated coaxial line (SICL)-based RL is designed, fabricated and tested, for accurate beamforming with extremely low feed line insertion loss. This article presents a complete design, development and performance analysis of an SICL-based RL beamformer. By using an SICL, isolation of up to 15 dB is achieved between the input beam ports of the RL, while the mutual coupling is kept at less than 20 dB. The SICL design shows a −10 dB insertion loss between the array and beam ports when compared to the same RL developed using MSL technology having an insertion loss of −15 dB. Due to the use of low-loss SICL technology, a realized gain of up to 14.2 dBi is achieved with an excellent scanning capability of −30 to 30 degrees, verifying for the first time the beamforming capabilities associated with SICL technology. The operational frequency band is 20–45 GHz, while the center operating frequency is 26 GHz making it appropriate for above 6-GHz 5G New Radio (NR) operating bands n257 (26.5 GHz to 29.5 GHz), n258 (24.25 GHz to 27.5 GHz), n261 (27.5 GHz to 28.35 GHz) and n260 (37 GHz to 40 GHz). Owing to the low-loss and stable beamforming performance, the SICL RL is suitable for mm-Wave 5G and is extendable to B5G applications.
10
Lotvall, J. O., R. J. Lemen, K. P. Hui, P. J. Barnes, and K. F. Chung. "Airflow obstruction after substance P aerosol: contribution of airway and pulmonary edema." Journal of Applied Physiology 69, no. 4 (October 1, 1990): 1473–78. http://dx.doi.org/10.1152/jappl.1990.69.4.1473.
Full textAbstract:
We have studied the effects of aerosolized substance P (SP) in guinea pigs with reference to lung resistance and dynamic compliance changes and their recovery after hyperinflation. In addition, we have examined the concomitant formation of airway microvascular leakage and lung edema. Increasing breaths of SP (1.5 mg/ml, 1.1 mM), methacholine (0.15 mg/ml, 0.76 mM), or 0.9% saline were administered to tracheostomized and mechanically ventilated guinea pigs. Lung resistance (RL) increased dose dependently with a maximum effect of 963 +/- 85% of baseline values (mean +/- SE) after SP (60 breaths) and 1,388 +/- 357% after methacholine (60 breaths). After repeated hyperinflations, methacholine-treated animals returned to baseline, but after SP, mean RL was still raised (292 +/- 37%; P less than 0.005). Airway microvascular leakage, measured by extravasation of Evans Blue dye, occurred in the brain bronchi and intrapulmonary airways after SP but not after methacholine. There was a significant correlation between RL after hyperinflation and Evans Blue dye extravasation in intrapulmonary airways (distal: r = 0.89, P less than 0.005; proximal: r = 0.85, P less than 0.01). Examination of frozen sections for peribronchial and perivascular cuffs of edema and for alveolar flooding showed significant degrees of pulmonary edema for animals treated with SP compared with those treated with methacholine or saline. We conclude that the inability of hyperinflation to fully reverse changes in RL after SP may be due to the formation of both airway and pulmonary edema, which may also contribute to the deterioration in RL.
11
Ogielska, Maria, Piotr Kierzkowski, and Mariusz Rybacki. "DNA content and genome composition of diploid and triploid water frogs belonging to the Rana esculenta complex (Amphibia, Anura)." Canadian Journal of Zoology 82, no. 12 (December 1, 2004): 1894–901. http://dx.doi.org/10.1139/z04-188.
Full textAbstract:
The Central European water frog Rana esculenta L., 1758 is a natural hybrid between Rana lessonae Camerano, 1882 (LL) and Rana ridibunda Pallas, 1771 (RR). Hybrids are usually diploid (RL) or triploid (LLR or RRL). Distinguishing LL from RL, RR from RL, and LLR from RRL according to external morphology is ambiguous. In this study we checked whether the DNA content in erythrocyte nuclei measured by image cytometry is useful in determination of the taxonomic status of diploids (LL, RR, and RL) and the genome composition of triploids (LLR and RRL). For exact and direct identification of parental species, as well as for determination of genome composition in hybrids, we applied actinomycin D – 4',6-diamidino-2-phenylindole chromosome staining to metaphase plates. We analyzed 43 LL, 12 RR, and 32 RL diploids, and 37 LLR and 19 RRL triploids. All diploid hybrids had 2n = 26 chromosomes, and all triploid hybrids had 3n = 39 chromosomes. Neither aneuploid nor mosaic hybrids were detected. The expected numbers of 13 R. lessonae (L) and 13 R. ridibunda (R) chromosomes in RL hybrids were recorded in about 31% of individuals. In the rest of the sample the composition was variable, ranging from 9 to 14 R chromosomes and the corresponding number of L chromosomes. The expected composition of 26 L and 13 R chromosomes was detected in about 32% of LLR triploids, whereas in the rest of the sample the composition of chromosomes ranged from 8 to 15 R chromosomes and the corresponding number of L chromosomes. The expected numbers of 26 R and 13 L chromosomes were detected in about 26% of RRL triploids, whereas in the rest of the sample the composition of chromosomes ranged from 19 to 28 R chromosomes and the corresponding number of L chromosomes. The DNA content densitometry showed that RR and RL diploids had 9.5% and 3.8% more DNA, respectively, than LL diploids. These differences, although statistically significant, were not sufficient to unequivocally discriminate LL from RL and RR from RL. Triploids had about 50% more DNA than LL diploids (49% in LLR and 51% in RRL), but these differences were too small for unequivocal determination of their genome composition.
12
Kolesnikov, Evgeniy N., Oleg Ivanovich Kit, Elena Frantsiyants, Valeria A. Bandovkina, Larisa S. Kozlova, Mikhail Anatolievich Kozhushko, Tanzila Beksultanovna Kazieva, Sergey V. Sanamyants, and Vladimir Trifanov. "Correlation of tissue plasminogen regulators expressed by esophageal adenocarcinoma with VEGF family members." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 37. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.37.
Full textAbstract:
37 Background: Esophageal cancer is known for its high potential of early lymphogenous metastases. The biological activity of plasminogen (PG) regulators, VEGFs and their receptors controls the growth and differentiation of cells, including malignant ones, the stability of the extracellular matrix, as well as processes of destruction of membranes and extracellular matrix, invasion of malignant cells, angio- and lymphangiogenesis. Our purpose was to study the role of PG regulators in the activation of VEGFs and their receptors in esophageal adenocarcinoma (EA) and its perifocal zone (PZ). Methods: Levels of uPA-Ag, uPA-act; tPA-Ag, tPA-act; PAI-1-Ag and PAI-1-act, VEGF-А, VEGF-R1, VEGF-С and VEGF-R3 were determined by ELISA in surgical specimens of EA (n = 28, st II, G2, T2-3N0-1M0). Statistical analysis was performed using Microsoft Office Excel 2010. Results: Levels of all proteins, except tPA, were higher in tumor (T) tissues than in the resection line (RL, p < 0.01). Protein levels, except uPA-Ag and tPA, in PZ were between levels in T and RL (p < 0.01); uPA-Ag, tPA-Ag and tPA-act were decreased in T and PZ compared with RL (p < 0.01); PAI-1-Ag in T and PZ was higher than in RL by 9.4 and 6.3 times, and PAI-1-act – by 10.7 and 1.9 times. Levels of VEGF-А, VEGF-R1, VEGF-С and VEGF-R3 were increased in T (p < 0.001), and in PZ they were between levels in T and RL (p < 0.001). Strong correlations were registered in EA T between uPA and VEGF-А (r = 86), uPA and VEGF-R1 (r = 81), uPA and VEGF-С (r = 79), uPA and VEGF-R3 (r = 76). A strong correlation between uPA and PAI-1 in T (r = 88) did not exclude PAI-1 biological effects in EA T and its PZ. PZ showed strong correlations between uPA and PAI-1 (r = 87), uPA and VEGF-А (r = 84), uPA and VEGF-С (r = 78). Conclusions: The strong correlations between the activation of uPA, PAI-1, VEGF-А, VEGF-С and their receptors in EA indicate interactions between them, realized both directly and through plasmin. The expression of the studied proteins in T and its PZ, compared to RL, demonstrates the effect of T on the content and activity of uPA, PAI-1, VEGF-A, VEGF-C and their receptors, with the following realization of biological properties that promote the progression of EA.
13
Torres, Franz, Adrian Mallma, Americo Munayco, Oscar Sotomayor, Franco Mauricio, and Frank Mayta-Tovalino. "Antibacterial Effect of Red Laser Therapy on Enterococcus faecalis Using Different Photosensitizers: An In Vitro Study." International Journal of Dentistry 2022 (February 10, 2022): 1–5. http://dx.doi.org/10.1155/2022/7408554.
Full textAbstract:
Objective. To assess the antibacterial effect of red laser using different photosensitizers such as methylene blue and malachite green on monoradicular premolars contaminated with E. faecalis ATCC 29212. Methods. This was an in vitro experimental study. Monoradicular premolars (44, 45, 34, and 35) were used, which were treated with ProTaper Next. After instrument change, irrigation, disinfection, and aspiration were performed with 2 ml of 4% NaOCl with a NaviTip 30°G needle (Ultradent, South Jordan, UT, USA). Group 1: RL + MB (red laser associated with methylene blue photosensitizer), group 2: RL + MG (red laser associated with malachite green photosensitizer), and group 3: control (no treatment). The E. faecalis strain was cultured on trypticase soy agar (TSB) (Difco, Detroit, MI, USA) and incubated at 37°C for 24 h. After the incubation period, colony-forming units (CFU/ml) of each group were counted using the plate count method. The ANOVA test was used with a significance level of p < 0.05 . Results. Group 1 had the lowest antibacterial contamination as it averaged only 530 ± 581.3 CFU/ml, while group 2 had the highest contamination with an average of 1990 ± 542.5 CFU/ml. Comparison revealed that there were statistically significant differences between the RL + MB and RL + MG groups ( p < 0.001 ). Conclusions. Group 1 had the best antimicrobial potential because it presented the lowest contamination in CFU/ml of E. faecalis compared to group 2 and group 3.
14
Koenraadt, Wilke M. C., Hans-Marc J. Siebelink, Margot M. Bartelings, Martin J. Schalij, Maureen J. van der Vlugt, Annemien E. van den Bosch, Ricardo P. J. Budde, et al. "Coronary anatomy in Turner syndrome versus patients with isolated bicuspid aortic valves." Heart 105, no. 9 (October 27, 2018): 701–7. http://dx.doi.org/10.1136/heartjnl-2018-313724.
Full textAbstract:
ObjectiveVariations in coronary anatomy, like absent left main stem and left dominant coronary system, have been described in patients with Turner syndrome (TS) and in patients with bicuspid aortic valves (BAV). It is unknown whether coronary variations in TS are related to BAV and to specific BAV subtypes.AimTo compare coronary anatomy in patients with TS with/without BAV versus isolated BAV and to study BAV morphology subtypes in these groups.MethodsCoronary anatomy and BAV morphology were studied in 86 patients with TS (20 TS-BAV, 66 TS-tricuspid aortic valve) and 86 patients with isolated BAV (37±13 years vs 42±15 years, respectively) by CT.ResultsThere was no significant difference in coronary dominance between patients with TS with and without BAV (25% vs 21%, p=0.933). BAVs with fusion of right and left coronary leaflets (RL BAV) without raphe showed a high prevalence of left coronary dominance in both TS-BAV and isolated BAV (both 38%). Absent left main stem was more often seen in TS-BAV as compared with isolated BAV (10% vs 0%). All patients with TS-BAV with absent left main stem had RL BAV without raphe.ConclusionThe equal distribution of left dominance in RL BAV without raphe in TS-BAV and isolated BAV suggests that presence of left dominance is a feature of BAVs without raphe, independent of TS. Both TS and RL BAV without raphe seem independently associated with absent left main stems. Awareness of the higher incidence of particularly absent left main stems is important to avoid complications during hypothermic perfusion.
15
Lv, Gongbo, Xing Zheng, Yitian Duan, Yunyong Wen, Bin Zeng, Mingqiang Ai, and Bin He. "The GRAS gene family in watermelons: identification, characterization and expression analysis of different tissues and root-knot nematode infestations." PeerJ 9 (May 26, 2021): e11526. http://dx.doi.org/10.7717/peerj.11526.
Full textAbstract:
The family of GRAS plant-specific transcription factor plays diverse roles in numerous biological processes. Despite the identification and characterization of GRAS genes family in dozens of plant species, until now, GRAS members in watermelon (Citrullus lanatus) have not been investigated comprehensively. In this study, using bioinformatic analysis, we identified 37 GRAS genes in the watermelon genome (ClGRAS). These genes are classified into 10 distinct subfamilies based on previous research, and unevenly distributed on 11 chromosomes. Furthermore, a complete analysis was conducted to characterize conserved motifs and gene structures, which revealed the members within same subfamily that have analogous conserved gene structure and motif composition. Additionally, the expression pattern of ClGRAS genes was characterized in fruit flesh and rind tissues during watermelon fruit development and under red light (RL) as well as root knot nematode infestation. Finally, for verification of the availability of public transcriptome data, we also evaluated the expression levels of randomly selected four ClGRAS genes under RL and nematode infection by using qRT-PCR. The qRT-PCR results indicated that several ClGRAS genes were differentially expressed, implying their vital role in RL induction of watermelon resistance against root-knot nematodes. The results obtained in this study could be useful in improving the quality of watermelon.
16
Frezoulis, Petros S., Elisavet Angelidou, Anastasia Diakou, Timoleon S. Rallis, and Mathios E. Mylonakis. "Optimization of fecal cytology in the dog: comparison of three sampling methods." Journal of Veterinary Diagnostic Investigation 29, no. 5 (May 8, 2017): 767–71. http://dx.doi.org/10.1177/1040638717709857.
Full textAbstract:
Dry-mount fecal cytology (FC) is a component of the diagnostic evaluation of gastrointestinal diseases. There is limited information on the possible effect of the sampling method on the cytologic findings of healthy dogs or dogs admitted with diarrhea. We aimed to: (1) establish sampling method–specific expected values of selected cytologic parameters (isolated or clustered epithelial cells, neutrophils, lymphocytes, macrophages, spore-forming rods) in clinically healthy dogs; (2) investigate if the detection of cytologic abnormalities differs among methods in dogs admitted with diarrhea; and (3) investigate if there is any association between FC abnormalities and the anatomic origin (small- or large-bowel diarrhea) or the chronicity of diarrhea. Sampling with digital examination (DE), rectal scraping (RS), and rectal lavage (RL) was prospectively assessed in 37 healthy and 34 diarrheic dogs. The median numbers of isolated ( p = 0.000) or clustered ( p = 0.002) epithelial cells, and of lymphocytes ( p = 0.000), differed among the 3 methods in healthy dogs. In the diarrheic dogs, the RL method was the least sensitive in detecting neutrophils, and isolated or clustered epithelial cells. Cytologic abnormalities were not associated with the origin or the chronicity of diarrhea. Sampling methods differed in their sensitivity to detect abnormalities in FC; DE or RS may be of higher sensitivity compared to RL. Anatomic origin or chronicity of diarrhea do not seem to affect the detection of cytologic abnormalities.
17
Su, Xiao-Li, Qi Tian, Jie Zhang, Xian-Zheng Yuan, Xiao-Shuang Shi, Rong-Bo Guo, and Yan-Ling Qiu. "Acetobacteroides hydrogenigenes gen. nov., sp. nov., an anaerobic hydrogen-producing bacterium in the family Rikenellaceae isolated from a reed swamp." International Journal of Systematic and Evolutionary Microbiology 64, Pt_9 (September 1, 2014): 2986–91. http://dx.doi.org/10.1099/ijs.0.063917-0.
Full textAbstract:
A strictly anaerobic, mesophilic, carbohydrate-fermenting, hydrogen-producing bacterium, designated strain RL-CT, was isolated from a reed swamp in China. Cells were Gram-stain-negative, catalase-negative, non-spore-forming, non-motile rods measuring 0.7–1.0 µm in width and 3.0–8.0 µm in length. The optimum temperature for growth of strain RL-CT was 37 °C (range 25–40 °C) and pH 7.0–7.5 (range pH 5.7–8.0). The strain could grow fermentatively on yeast extract, tryptone, arabinose, glucose, galactose, mannose, maltose, lactose, glycogen, pectin and starch. The main end products of glucose fermentation were acetate, H2 and CO2. Organic acids, alcohols and amino acids were not utilized for growth. Yeast extract was not required for growth; however, it stimulated growth slightly. Nitrate, sulfate, sulfite, thiosulfate, elemental sulfur and Fe(III) nitrilotriacetate were not reduced as terminal electron acceptors. Aesculin was hydrolysed but not gelatin. Indole and H2S were produced from yeast extract. The G+C content of the genomic DNA was 51.2 mol%. The major cellular fatty acids were iso-C15 : 0, anteiso-C15 : 0 and C16 : 0. The most abundant polar lipid of strain RL-CT was phosphatidylethanolamine. 16S rRNA gene sequence analysis revealed that the isolate belongs to the uncultured Blvii28 wastewater-sludge group (http://www.arb-silva.de/) in the family Rikenellaceae of the phylum Bacteroidetes, and shared low sequence similarities with the related species Alistipes shahii WAL 8301T (81.8 %), Rikenella microfusus ATCC 29728T (81.7 %) and Anaerocella delicata WN081T (80.9 %). On the basis of these data, a novel species in a new genus of the family Rikenellaceae is proposed, Acetobacteroides hydrogenigenes gen. nov., sp. nov. The type strain of the type species is RL-CT ( = JCM 17603T = DSM 24657T = CGMCC 1.5173T).
18
Thalacker-Mercer, Anna E., Louis J. Dell'Italia, Xiangqin Cui, James M. Cross, and Marcas M. Bamman. "Differential genomic responses in old vs. young humans despite similar levels of modest muscle damage after resistance loading." Physiological Genomics 40, no. 3 (February 2010): 141–49. http://dx.doi.org/10.1152/physiolgenomics.00151.2009.
Full textAbstract:
Across numerous model systems, aging skeletal muscle demonstrates an impaired regenerative response when exposed to the same stimulus as young muscle. To better understand the impact of aging in a human model, we compared changes to the skeletal muscle transcriptome induced by unaccustomed high-intensity resistance loading (RL) sufficient to cause moderate muscle damage in young (37 yr) vs. older (73 yr) adults. Serum creatine kinase was elevated 46% 24 h after RL in all subjects with no age differences, indicating similar degrees of myofiber membrane wounding by age. Despite this similarity, from genomic microarrays 318 unique transcripts were differentially expressed after RL in old vs. only 87 in young subjects. Follow-up pathways analysis and functional annotation revealed among old subjects upregulation of transcripts related to stress and cellular compromise, inflammation and immune responses, necrosis, and protein degradation and changes in expression (up- and downregulation) of transcripts related to skeletal and muscular development, cell growth and proliferation, protein synthesis, fibrosis and connective tissue function, myoblast-myotube fusion and cell-cell adhesion, and structural integrity. Overall the transcript-level changes indicative of undue inflammatory and stress responses in these older adults were not mirrored in young subjects. Follow-up immunoblotting revealed higher protein expression among old subjects for NF-κB, heat shock protein (HSP)70, and IL-6 signaling [total and phosphorylated signal transducer and activator of transcription (STAT)3 at Tyr705]. Together, these novel findings suggest that young and old adults are equally susceptible to RL-mediated damage, yet the muscles of older adults are much more sensitive to this modest degree of damage—launching a robust transcriptome-level response that may begin to reveal key differences in the regenerative capacity of skeletal muscle with advancing age.
19
Jenne, J. W., T. K. Shaughnessy, W. S. Druz, C. J. Manfredi, and R. E. Vestal. "In vivo functional antagonism between isoproterenol and bronchoconstrictants in the dog." Journal of Applied Physiology 63, no. 2 (August 1, 1987): 812–19. http://dx.doi.org/10.1152/jappl.1987.63.2.812.
Full textAbstract:
The functional antagonism between isoproterenol and methacholine, histamine and serotonin, as described in vitro in respiratory smooth muscle was explored in vivo in a canine model. Infusions of isoproterenol were administered during brief peaks of bronchospasm produced by aerosolized methacholine and histamine, or during sustained bronchospasm produced by infused serotonin. In eight mongrel dogs anesthetized with pentobarbital sodium, the mean protection by infused isoproterenol against methacholine challenge decreased from 60.6 to 29.1% as the mean lung resistance (RL) was increased from 78 to 232% over base line by a fourfold increase in methacholine (P less than 0.002). In six dogs, the mean protection by isoproterenol against histamine decreased from 55.5 to 26.9% as the opposing RL increased from 80 to 182% over base line with a fourfold increase in histamine (P less than 0.02). However, with serotonin infusions there was only a small 18% mean decrease in protection (P = 0.05), associated with a correspondingly small 37% mean increase in dose of serotonin despite a 269% mean increase in resistance (P = 0.02). In all cases, the loss of protection correlated more closely with the dose of constrictant than the resistance increase over base line. These findings demonstrate in vivo functional antagonism between isoproterenol and the dose of bronchoconstrictant but not necessarily resistance increase per se.
20
Marantz, Monica J., Sandra G. Vincent, and John T. Fisher. "Role of vagal C-fiber afferents in the bronchomotor response to lactic acid in the newborn dog." Journal of Applied Physiology 90, no. 6 (June 1, 2001): 2311–18. http://dx.doi.org/10.1152/jappl.2001.90.6.2311.
Full textAbstract:
We addressed the hypothesis that vagal C-fiber afferents and cyclooxygenase products are the mechanisms responsible for lactic acid (LA)-induced bronchoconstriction in the newborn dog. Perineural capsaicin and indomethacin were used to block conduction of vagal C fibers and production of cyclooxygenase products, respectively. Perineural capsaicin eliminated (85%) the increase in lung resistance (Rl; 45 ± 5.6%) due to capsaicin (25 μg/kg), whereas the increase in Rl (54 ± 6.9%) due to LA (0.4 mmol/kg) was only inhibited by 37 ± 4.7% ( P < 0.05). Atropine reduced LA-induced bronchoconstriction (42 ± 2.1%) by an amount similar to that obtained with perineural capsaicin. However, inhibition was significantly increased when atropine was combined with indomethacin (61 ± 2.7%; P < 0.05), implicating cyclooxygenase products in the LA-induced bronchoconstrictor response. We conclude that the mechanisms responsible for LA-induced bronchoconstriction in the newborn are 1) activation of vagal C-fibers, which, through projections to medullary respiratory centers, leads to activation of vagal cholinergic efferents; 2) production of cyclooxygenase products, which cause bronchoconstriction independent of medullary involvement; and 3) an unknown bronchoconstrictor mechanism, putatively tachykinin mediated. On the basis of our data, pharmaceutical targeting of pulmonary afferents would prevent multiple downstream mechanisms that lead to airway narrowing due to inflammatory lung disease.
21
Ahn, Hyo-Won, Sung Chul Moon, and Seung-Hak Baek. "Morphometric evaluation of changes in the alveolar bone and roots of the maxillary anterior teeth before and after en masse retraction using cone-beam computed tomography." Angle Orthodontist 83, no. 2 (October 15, 2012): 212–21. http://dx.doi.org/10.2319/041812-325.1.
Full textAbstract:
ABSTRACT Objective: To evaluate the morphometric changes in the alveolar bone and roots of the maxillary anterior teeth (MXAT) after en masse retraction with maximum anchorage (EMR-MA). Materials and Methods: The samples consisted of 37 female adult patients who had Class I dentoalveolar protrusion (CI-DAP) and were treated by extraction of the first premolars and EMR-MA. Using three-dimensional cone-beam computed tomography taken before treatment and after space closure, the maxillary central incisors (MXCI, N = 66), lateral incisors (MXLI, N = 69), and canines (MXC, N = 69) were superimposed using individual reference planes. After alveolar bone area (ABA), vertical bone level (VBL), root length (RL), root area (RA), and prevalence of dehiscence (PD) were measured at the cervical, middle, and apical levels, statistical analyses were performed. Results: On the palatal side, ABA significantly decreased in all levels of MXAT (P < .001; middle of MXC, P < .01). MXCI and MXLI exhibited a greater decrease in the ratio of change in palatal ABA than did MXC (cervical, P < .01; middle and apical, P < .05; total, P < .001). Palatal/labial ABA ratios decreased in MXCI (cervical, middle, total, P < .001; apical, P < .05) and MXLI (cervical, P < .001; apical, P < .05). They showed greater amounts and ratios of change in VBL on the palatal side compared to the labial side (all P < .001). The palatal side showed more PD in the cervical area than did the labial side (MXCI and MXLI, P < .001; MXC, P < .01). Significant root resorption occurred in MXAT (RL and RA, all P < .001). Conclusions: During EMR-MA in cases with CI-DAP, ABA and VBL on the palatal side and RL and RA of MXCI and MXLI were significantly decreased.
22
Franco, J. A., S. Bañón, J. A. Fernández, and A. González. "262 Nursery Irrigation Effects on Postplanting Root Development of Two Mediterranean Species in Semi-arid Conditions." HortScience 34, no. 3 (June 1999): 487C—487. http://dx.doi.org/10.21273/hortsci.34.3.487c.
Full textAbstract:
A study was conducted with Lotus creticus and Limonium cossonianum to analyze the influence of irrigation regime in nursery on the dynamics of root development after being transplanted with minimum management conditions. Plants were pot-grown in a greenhouse located at the southeastern Mediterranean coast of Spain (37°47′N, 0°54′W). Each plant was potted into 625-mL plastic pot filled with a 1 silica sand medium: 1 peat (v/v) mixture amended with osmocote plus (3.7 g•kg-1 substrate). Drip irrigation was used, with a 2-L•h-1 emitter per plant. Three irrigation treatments were utilized: T6, plants watered 6 days a week at the water-holding capacity (leaching ≈20% of the applied water); T3, plants watered 3 days a week; and T2, plants watered twice a week. T3 and T2 plants received amounts of water at ≈50% and ≈30%, respectively, of T6 plants troughout the nursery period (3 months for Lotus and 45 days for Limonium). After nursery period, plants were transplanted into transparent containers (round acrylic tubes 8 cm in diameter and 100 cm tall) filled with silt loam texture soil, and just one establishment irrigation was applied (30 mm). Containers were covered with a black plastic sheet and isolating material to prevent light influencing and becoming heated. There were three replications. Plant root and top growth were measured every 3 days for 1 month. Results indicate that those plants that were less watered in nursery showed a greater and faster root development especially where depth was concerned. Lotus plants root growth, for the top 20 cm of soil, were not significantly affected by irrigation treatments; between 20 and 40 cm deep, T2 plants at 12 days after transplanting (DAT) had 2.8- and 9.1-times greater root length (RL) than T3 and T6 plants, respectively. At 30 DAT, T2 plants had 1.7- and 6.2-times higher RL than T3 and T6, respectively. Under 40-cm deep (where infiltration of the establishment irrigation water was very limited), only T2 plants developed roots. There was no plant top growth throughout this period. Limonium plants exhibited notably lower root development (≈1/5) than Lotus plants. In the top 15 cm of soil, Limonium plants RL were not significantly affected by irrigation treatment; between 15 and 30 cm deep, T2 and T3 plants, at 10 DAT, had 2.2-times longer RL than T6 plants, and at 30 DAT, T2 plants had 1.4- and 2.1-times greater RL than T3 and T6 plants, respectively. Below 30 cm, only T2 plants developed roots and, even so, very few ones. For this period, a slight plant top growth was observed, there being no significant differences among irrigation treatments. Research suported by CICYT grant AGF-96-1136-C02-02.
23
Kirinus, Marines Batalha Moreno, Keilor da Rosa Dorneles, Pricila Santos Silva, Caroline Farias Barreto, Roberto Pedroso Oliveira, and Marcelo Barbosa Malgarim. "Application of chemical compounds during pre-harvesting to control post-harvesting green mold in citrus." Semina: Ciências Agrárias 42, no. 4 (May 20, 2021): 2135–50. http://dx.doi.org/10.5433/1679-0359.2021v42n4p2135.
Full textAbstract:
This study aimed to evaluate the effect of system-acquired resistance inducing compounds applied during the pre-harvest of ‘Navelina’ orange and ‘Ortanique’ tangor in controlling post-harvest disease caused by Penicillium digitatum. The products applied were acibenzolar-s-methyl (ASM), imidacloprid (IMI), methyl jasmonate (MeJa), sodium selenite, potassium silicate, and thiamethoxam (TMT). Sterile distilled water was used as the control. The applications were administered 45, 30, and 15 days before harvesting. In 2015 and 2016, 840 fruits were randomly collected, and when they reached commercial maturation, they were sanitized, half were pierced with a needle in the equatorial region. The fruits were inoculated with a 10 μL spore suspension (1 × 106 conidia mL-1) of P. digitatum, in the equatorial region. The experiment was performed with three replicates, each comprising 10 fruits and repeated over two consecutive crop seasons. Disease incidence was evaluated on pierced (at 72 and 144 h after inoculation [hai]) and unperforated (at 360 hai) fruits. For pierced fruits, lesion expansion rate (rL), disease severity, expansion rate of sporulating area (rE), and sporulating area were evaluated. The area under the disease progress curve (AUDPC) and the area under the sporulating area progress curve were calculated. Both cultivars were susceptible; however, the rL and rE had lower values for ‘Ortanique’. The tested products reduced the disease incidence in both cultivars. Potassium silicate reduced rL and rE, whereas sodium selenite reduced rE. The disease severity was reduced by potassium silicate, sodium selenite, and ASM. AUDPC was reduced by sodium selenite and potassium silicate treatments. Among the tested products, potassium silicate and sodium selenite applied during the pre-harvest of ‘Navelina’ orange and ‘Ortanique’ tangor had the highest reductions for disease incidence (ranging from 14% to 37%, respectively) and severity (60% and 70%, respectively), rE (50% for both compounds), and total sporulating area (55% and 56%, respectively), reducing the green mold in postharvested fruits caused by P. digitatum.
24
FAROOQ, AMEEQ, KASHIF MAIRAJ DEEN, MUHAMMAD RIZWAN, and AKHLAQ AHMAD. "SURFACE MODIFICATION OF COMMERCIALLY PURE TITANIUM BY GOLD-ION IRRADIATION FOR BIOMEDICAL APPLICATIONS." Surface Review and Letters 28, no. 09 (May 8, 2021): 2150069. http://dx.doi.org/10.1142/s0218625x21500694.
Full textAbstract:
This research work’s aim was to enhance the biocompatibility of the commercially pure titanium (cpTi-2) surface via Au-ion irradiation. Various ion dosages, i.e. [Formula: see text] (Au-11), [Formula: see text] (Au-12) and [Formula: see text] (Au-13) ions[Formula: see text][Formula: see text][Formula: see text]cm[Formula: see text], were produced by exposing the polished cpTi-2 samples to Au-ion beam at room temperature. The surface topographic features of cpTi-2 and the effects of Au-ion-implanted surfaces were examined by atomic force microscopy and XRD analysis. Open-Circuit Potential (OCP), Potentiodynamic Polarization Scans (PPS) and Electrochemical Impedance Spectroscopy (EIS) were used to compare the electrochemical behavior of the cpTi-2 and Au-ion-implanted samples in Ringer’s lactate (RL) solution at 37∘C. The effects of Au-ion irradiation on the proliferation of mesenchymal stem cells (MSCs) were estimated during 24[Formula: see text]h and 48[Formula: see text]h of exposure. Based on the experimental results, Au-12 samples presented more positive OCP and lower corrosion rate in RL solution than the Au-11 and Au-13 samples. No significant change in the morphology of the MSCs was observed after exposure to the Au-ion-implanted samples. Similar to the controlled medium, the percentage of viability of the cells of the cells on Au-12 increased from 75% to 165% on the surface of Au-13 samples during 48[Formula: see text]h of incubation indicating the positive effects of Au-ion irradiation for biocompatibility.
25
Kimby, Eva, Giovanni Martinelli, Bjorn Ostenstad, Ulrich JM Mey, Daniel Rauch, Björn E. Wahlin, Felicitas Hitz, et al. "Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10." Blood 124, no. 21 (December 6, 2014): 799. http://dx.doi.org/10.1182/blood.v124.21.799.799.
Full textAbstract:
Abstract Background: Previous trials from the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) showed that therapy with single-agent rituximab can produce long-term remissions in a sizeable subset of follicular lymphoma (FL) patients, with overall survival not inferior to chemo-immunotherapy, providing the rationale for the development of chemotherapy-free treatment strategies. Promising results have also been reported with the combination of rituximab and lenalidomide. The SAKK 35/10 phase-2 study was developed and conducted by the SAKK in cooperation with the NLG to compare the activity of rituximab plus lenalidomide versus single-agent rituximab in the first-line FL therapy. Methods: Patients with histologically confirmed untreated FL, grade 1, 2, 3a and in need of systemic therapy, were randomized either to rituximab monotherapy (R) (8 infusions of 375mg/m2 at day 1 of weeks 1, 2, 3, 4, and repeated at day 1 of weeks 12, 13, 14 and 15) or to rituximab (given at the same schedule) in combination with lenalidomide (RL) (lenalidomide given orally, 15 mg daily, starting 14 days before the first rituximab administration and continuously until 14 days after the last). The primary endpoint was the complete response (CR/CRu) assessed at week 23, defined according to the NCI standardized criteria (Cheson et al 1999). The study sample size was calculated to allow the detection of a 20% increase of the CR/CRu rate with RL over R, with 90% power and a type I error of 0.10. The 2 arms were compared using a one-sided Z-test with unpooled variance for proportions. Trial treatment was discontinued in patients who at week 10 did not achieve at least a minimal response, defined as reduction of more than 25% in the sum of product of tumor diameters (SPD), and rescue chemotherapy was given at the discretion of the treating physician. Results: In total, 154 patients were randomized; 77 (40 women and 37 men; median age 63yrs, range 29-85; 52% with stage IV and 47% with poor-risk FLIPI score) were allocated to arm R and 77 (42 women and 35 men; median age 61yrs, range 26-80; 48% with stage IV and 47% with poor-risk FLIPI score) to arm RL. Treatment was discontinued by 21 (28%) patients in arm R, in 16 due to lack of response at week 10 and in 1 due to toxicity, and by 19 (25%) patients in arm RL, in 3 due to lack of response at week 10 and in 13 due to toxicity. Adverse events of any grade were reported in 91% of patients in arm R and 100% in arm RL and adverse events of grade ≥3 were more common in arm RL than in arm R (51% vs 18% of patients). Grade 3-4 neutropenia was observed in 5% of patients in arm R and 19% in arm RL. The primary endpoint analysis (using the response assessment from the local investigators, reviewed by the study chairs) showed a significantly higher CR/CRu rate in patients treated with RL in comparison with those receiving R. This difference was observed both in the intent-to-treat (CR/CRu rate, 36% vs. 25%, respectively; p=0.056) and the per-protocol population (CR/CRu rate, 42% vs. 28%, respectively; p=0.049). Conclusions: The addition of lenalidomide to rituximab results in a significantly better CR/CRu at the cost of an expected increased toxicity. Further follow-up is needed to ascertain whether the response improvement will translate into prolonged time to next treatment and superior progression-free and overall survival rates. TableInvestigators’ assessment of the response at week 23 in the intent-to-treat (ITT) population Rituximab (N=77) Rituximab+Lenalidomide (N=77)Response category n (%)[95% C.I.]n (%)[95% C.I.]CR/CRu19 (25) [16-36%]28 (36)[26-48%] PR28 (36) [26-48%]35 (45)[34-57%]SD6 (8) [3-16%]4 (5)[1.4-13%]PD/relapse2 (3) [0.3-9%]3 (4)[0.8-11%]Not evaluable*22 (29) [19-40%]7 (9)[4-18%]*Patients with no assessment at week 23, including patients not achieving at least a minimal response at week 10. Disclosures Kimby: Roche: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Off Label Use: Lenalidomide, not approved for follicular lymphoma. Mey:Celgene: Membership on an entity's Board of Directors or advisory committees. Ferreri:Celgene: Research Funding. Bargetzi:Celgene: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees. Krasniqi:Roche, Takeda: Membership on an entity's Board of Directors or advisory committees. Zucca:Roche, Mundivarma, Novartis: Consultancy, Honoraria, Research Funding.
26
Keerthi, Nemalidinne, Mohan Kumar K., Bhaskaran A., Krishna Prasad K., Shashirekha C. A., Prakash Dave, and Sreeramulu P. N. "Clinical efficacy of two anti-microbials (ceftriaxone and metronidazole) versus three antimicrobials (ceftriaxone, metronidazole and amikacin) in perforative peritonitis." International Surgery Journal 5, no. 11 (October 26, 2018): 3644. http://dx.doi.org/10.18203/2349-2902.isj20184638.
Full textAbstract:
Background: Peritonitis is classified as primary, secondary and tertiary. In primary peritonitis and continuous ambulatory peritoneal dialysis-associated peritonitis, the source of the infection is not due a breach in the gastrointestinal tract and usually caused by a single organism. Secondary peritonitis ensues, which may be localized and contained or diffuse carrying a high mortality in the absence of surgical intervention and appropriate antimicrobial therapy. In contrast, secondary peritonitis following perforation of the gastrointestinal tract or an infection originating in an intra-abdominal structure. Tertiary peritonitis is an ill-defined entity, which occurs despite adequate treatment of primary or secondary peritonitis.Methods: This is a prospective clinical study conducted on 140 consecutive patients who presented to the surgical department of RL Jalappa Hospital and Research Centre, Tamaka, Kolar with peritonitis secondary to hollow viscus perforation.Results: A total of 140 patients who presented with peritonitis secondary to hollow viscus perforation, admitted and treated in RL Jalappa Hospital and Research Centre attached to Sri Devaraj Urs Medical College, Kolar were studied during the period of December 2015 to June 2017.There was decrease in postoperative complications and hospital stay in Group B.Conclusions: In present study peritonitis is more common in men compared to women. The most common age group is in between 21-40 years in cases of peritonitis with the mean age of 37 years. Duodenal ulcer perforation is the commonest site of perforation. Escherichia coli is the most common organism isolated in the peritoneal fluid. usage of three antimicrobials (p<0.05) is beneficial in reduction in postoperative complications and hospital stay when compared to usage of two antimicrobials which is statistically significant.
27
Abid, Mourad, Mohamed Amine Mansouri, Yousri Ballah, Mourad Brahimi, Zakia KordjanI, and Abdelhalim Hammani. "Benefits of hypofractionated radiotherapy in locally advanced adenocarcinoma’s treatment." Batna Journal of Medical Sciences (BJMS) 4, no. 2 (December 31, 2017): 159–62. http://dx.doi.org/10.48087/bjmsoa.2017.4207.
Full textAbstract:
Introduction : La prise en charge des adénocarcinomes (ADK) du bas et moyen rectums localement avancés est bien codifiée, reposant sur une radiothérapie néo-adjuvante (RTNA) suivie d’une chirurgie d’exérèse rectale carcinologique. Néanmoins, 2 techniques de radiothérapie (RT) font toujours débat : La radiothérapie hypo-fractionnée (RC), et la radio-chimiothérapie concomitante (RCC) longue. La première technique a été introduite au centre Pierre et Marie Curie d’Alger en Mai 2010 par un comité multidisciplinaire (Comité rectum), avec pour objectif principal de réduire le délai d’attente des patients. Méthodes : Dans notre étude, nous avons évalué l’impact quantitatif et qualitatif de l’introduction de la radiothérapie courte sur la prise en charge des patients. Un échantillon de 297 patients a été étudié sur une période de plus de dix ans. Nous avons pris Mai 2010 (introduction de la radiothérapie courte) comme point de référence pour diviser cet échantillon en deux groupes : groupe 1 : patients traités avant mai 2010 (n = 130) et groupe 2 : patients traités après mai 2010 (n = 167). Trois protocoles ont été utilisés : radio- chimiothérapie concomitante, radiothérapie longue sans chimiothérapie et radiothérapie courte. Nous avons évalué l’accès à la RTNA, la réponse tumorale à la radiothérapie, le taux de stérilisations complètes ainsi que celui des résections complètes R0. Résultats : Avant mai 2010, seulement 33% (43 /130) des patients ont bénéficié d’une RTNA (RC=2,5 % ; RCC=60,5 % ; RL= 37 %). Après mai 2010, 65 % (113/167) des patients ont pu accéder à une RTNA (RC= 73 % ; RCC= 21 % ; RL = 6 %). P< 0,001. Une stérilisation complète (ypT0N0) a pu être obtenue chez 13 patients (30 %) du groupe 1 et 2 patients (2 %) du groupe 2 (p<0,001). Conclusion : L’introduction de la radiothérapie courte a permis de doubler le nombre de patients recevant une radiothérapie néoadjuvante. Néanmoins, le taux de réponses complètes a significativement baissé.
28
Demari, Gustavo H., Vinícius J. Szareski, Ivan R. Carvalho, Tuane A. da Silva, Vânia M. Gehling, Danielli Olsen, Tamires S. Martins, et al. "Storage of Soybean Seeds and Addition of Insecticide and Micronutrients." Journal of Agricultural Science 11, no. 1 (December 15, 2018): 553. http://dx.doi.org/10.5539/jas.v11n1p553.
Full textAbstract:
The objective of this work was to evaluate the effects on the physiological attributes of soybean seeds submitted to the seed treatment with addition of insecticide, polymers and micronutrients throughout the storage. The experimental design was completely randomized in a factorial scheme, with four seed treatments per two seasons of storage of the seeds. The analysis of variance revealed a significant interaction among seed treatments and storage times for both cultivars at 5% of probability, referring to the characteristics of shoot length (SL), primary root length (RL), shoot dry mass (SDM) and dry mass of the primary root (RDM) for the cultivar Fundacep 37 RR. Addition of seed treatments influences the physiological performance of seedlings originated from soybean seeds stored for 240 days. The shoot and primary root lenghts, and shoot dry mass express the isoenzyme esterase through the aerial part and primary root of the seedling, the malate dehydrogenase is expressed in the primary root while in the peroxidase it is evident in the shoot of the seedlings.
29
Jaimes, Ruth Flavia Vera Villamil, Mónica Luisa Chaves de Andrade Afonso, Sizue Ota Rogero, Celso Antonio Barbosa, Alexandre Sokolowski, and Silvia Maria Leite Agostinho. "Estudo eletroquímico comparativo do aço ISO 5832-9 em diferentes meios de interesse biológico." Rem: Revista Escola de Minas 63, no. 1 (March 2010): 167–72. http://dx.doi.org/10.1590/s0370-44672010000100028.
Full textAbstract:
Foi estudado o comportamento eletroquímico a 37°C do aço inoxidável ISO 5832-9, em meios de NaCl 0,9 %, de Ringer Lactato e meio mínimo de Eagle (MEM), por voltametria linear e análises da superfície por microscopia eletrônica de varredura (MEV) e por espectroscopia por dispersão de energia (EDS). Foram feitos ensaios mecânicos e testes de toxicidade. O aço ISO 5832-9 se encontra passivado no potencial de corrosão e não apresenta corrosão por pite nos três meios estudados em toda faixa de potencial investigada, desde o potencial de corrosão até 50 mV acima do potencial de transpassivação. Em meio de MEM, no entanto, as análises por MEV e EDS mostraram que o referido aço, nesse valor mais elevado de potencial, apresentou um comportamento diferente, com perda das inclusões de óxido de manganês. Os potenciais de corrosão, Ecorr (potencial de circuito aberto estacionário) bem como os valores de densidade de corrente de passivação, variaram na seguinte ordem: Ecorr, RL < Ecorr, NaCl < Ecorr, MEM. e jMEM << jRL ≅ jNaCl. No ensaio de citotoxicidade, o aço foi caracterizado como não-tóxico.
30
Heaney, Mark L., Jeffrey R. Gardner, Nicos Karasavvas, David W. Golde, David A. Scheinberg, Emily A. Smith, and Owen A. O’Connor. "Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs." Blood 106, no. 11 (November 16, 2005): 498. http://dx.doi.org/10.1182/blood.v106.11.498.498.
Full textAbstract:
Abstract Vitamin C is an antioxidant vitamin that has been hypothesized to antagonize the effects of antineoplastic drugs that generate reactive oxygen species. Leukemia (K562) and lymphoma (RL) cells pre-treated with dehydroascorbic acid, the commonly transported form of vitamin C, demonstrated a dose-dependent attenuation of cytotoxicity after treatment with the widely-used antineoplastic drugs, doxorubicin, cisplatin, vincristine, methotrexate and imatinib that ranged from 30–80% as measured by trypan blue exclusion and colony formation in methylcellulose. While treatment with vitamin C alone did not appreciably alter tumor growth compared with untreated mice with xenogeneic tumors (RL) (p=0.114), mice treated with vitamin C prior to doxorubicin administration had tumors that were, on average, four times larger than tumors in mice treated with doxorubicin alone (p=0.01) at day 32 of treatment. This result indicates that vitamin C treatment can attenuate antineoplastic therapy in vivo. Pretreatment of cells with vitamin C led to a dose-dependent decrease in apoptosis with all agents tested. At the highest concentrations of intracellular vitamin C, the decrease in apoptosis ranged from 37–82% as measured by TUNEL. There was no change in P-glycoprotein expression in vitamin C-treated cells and no difference in doxorubicin concentrations in the tumors of vitamin C-treated mice suggesting that the inhibitory effects of vitamin C are not due to generalized effects of antineoplastic drug uptake or efflux. When K562 and RL cells were treated with antineoplastic agents, we found that, as has been previously reported, doxorubicin and, to a lesser extent, cisplatin, increased the intracellular levels of ROS, while other agents had little discernible effect on ROS levels. In cells treated with chemotherapeutic drugs, as well as in untreated cells, pretreatment of cells with vitamin C caused a small (<15%) reduction in intracellular levels of ROS. This modest reduction in intracellular ROS levels appeared to be minor in comparison to the reduction in cytotoxicity. While treatment with N-acetylcysteine only attenuated the cytotoxic effects of cisplatin, vitamin C pretreatment attenuated the effects of all drugs tested, suggesting a distinct mechanism of action. We found that all of the antineoplastic agents tested caused rapid mitochondrial membrane depolarization. Treatment with vitamin C prior to exposure to antineoplastic agents prevented mitochondrial membrane depolarization. Mitochondrial membrane potentials in vitamin C-treated cells 6 hr after treatment with chemotherapeutic drugs were similar to untreated control cells (p<0.003). A mitochondrial site of action was further supported by the finding that vitamin C antagonizes the cytotoxic effects of actinonin, an inhibitor of peptide deformylase. These findings suggest that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response to a broad range of anti-cancer drugs and point to preserved mitochondrial membrane potential as a mechanism of action.
31
Tall, Yara Al, Baha’a Al-Rawashdeh, Ahmad Abualhaijaa, Ammar Almaaytah, Majed Masadeh, and Karem H. Alzoubi. "Functional Characterization of a Novel Hybrid Peptide with High Potency against Gram-negative Bacteria." Current Pharmaceutical Design 26, no. 3 (March 18, 2020): 376–85. http://dx.doi.org/10.2174/1381612826666200128090700.
Full textAbstract:
Background: Multi-drug resistant infections are a growing worldwide health concern. There is an urgent need to produce alternative antimicrobial agents. Objective : The study aimed to design a new hybrid antimicrobial peptide, and to evaluate its antimicrobial activity alone and in combination with traditional antibiotics. Methods: Herein, we designed a novel hybrid peptide (BMR-1) using the primary sequences of the parent peptides Frog Esculentin-1a and Monkey Rhesus cathelicidin (RL-37). The positive net charge was increased, and other physicochemical parameters were optimized. The antimicrobial activities of BMR-1 were tested against control and multi-drug resistant gram-negative bacteria. Results: BMR-1 adopted a bactericidal behavior with MIC values of 25-30 µM. These values reduced by over 75% upon combination with conventional antibiotics (levofloxacin, chloramphenicol, ampicillin, and rifampicin). The combination showed strong synergistic activities in most cases and particularly against multi-drug resistance P. aeruginosa and E. coli. BMR-1 showed similar potency against all tested strains regardless of their resistant mechanisms. BMR-1 exhibited no hemolytic effect on human red blood cells with the effective MIC values against the tested strains. Conclusion: BMR-1 hybrid peptide is a promising candidate to treat resistant infectious diseases caused by gramnegative bacteria.
32
Liu, Xiao Ye, Zi Rui Guo, Yong Juan Zhang, Zhan Qing Wang, and Yong Feng Li. "The Molecular Characterization and Hydrogen Production of a New Species of Anaerobe in Wastewater Treatment Process for H2 Recovery." Advanced Materials Research 113-116 (June 2010): 1049–52. http://dx.doi.org/10.4028/www.scientific.net/amr.113-116.1049.
Full textAbstract:
The isolation and identification of hydrogen production bacteria(HPB)with high yield and high evolution rate is an important foundation of fermented hydrogen production process by anaerobic digesting high strength organic wastewater. An improved Hungater rolling tubes technique and a plate method of culture bottle (PMCB) were employed to enumerate and isolate the anaerobes. The HPB-RL medium was designed specially for isolating and culturing anaerobic hydrogen bacteria. Culture temperature was at 37°C and 5.5 of pH. About 90 strains of bacteria were isolated, in which, a strain of the hydrogen producer with high yield and high evolution rate was isolated and named Rennanqi12. The isolates were straight rods, Grams positive, strictly anaerobic, no spore-forming bacteria, whole bacteria flagella, having capsule, 3~4 metachromatic granules. The strain of Rennanqi12 could produce hydrogen using molasses wastewater as the carbon resource. The isolate Rennanqi12 has the closest relationship with the strain C. cellulose for the 94% homology of 16S rDNA. The strain of Rennanqi12 might be a new species that belongs to a new genus. The amount of hydrogen-producing (YH2)is 1880.5ml/L medium and the maximum hydrogen-producing rate(QH2)is 28.2 mmol/g•(dry•cell)•h when R12 digested substrates were glucose.
33
Lai, Wenwen, Yan Wang, and Junkun He. "Effects of Carbonyl Iron Powder (CIP) Content on the Electromagnetic Wave Absorption and Mechanical Properties of CIP/ABS Composites." Polymers 12, no. 8 (July 29, 2020): 1694. http://dx.doi.org/10.3390/polym12081694.
Full textAbstract:
Three-dimensional (3D) printing technology has proven to be a convenient and effective method to fabricate structural electromagnetic wave (EMW) absorbers with tunable EMW absorption properties. To obtain a functional material with strong EMW absorbing performance and excellent mechanical properties for fused deposition modeling (FDM) 3D printing technology, in this work, carbonyl iron powder (CIP)/acrylonitrile-butadiene-styrene copolymer (ABS) composites with different CIP contents were prepared by the melt-mixing process. The effects of the CIP content on the EMW absorption and mechanical properties of CIP/ABS composites were investigated. The CIP/ABS composite with a CIP content of 40 wt.% presented the lowest reflection loss (RL) of −48.71 dB for the optimal impedance matching. In addition, this composite exhibited optimal mechanical properties due to the good dispersion of the CIPs in the matrix ABS. Not only were the tensile and flexural strength similar to pure ABS, but the tensile and flexural modulus were 32% and 37% higher than those of pure ABS, respectively. With a CIP content of 40 wt.%, the CIP/ABS composite proved to be a novel functional material with excellent EMW absorbing and mechanical properties, providing great potential for the development of structural absorbers via FDM 3D printing technology.
34
Wagner, Charlotte Burton, Daniel Arthur Ermann, Kenneth M. Boucher, Adrienne Nedved, Ivana N. M. Micallef, Haris Hatic, Gaurav Goyal, et al. "Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?" Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 7514. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.7514.
Full textAbstract:
7514 Background: The AETHERA trial demonstrated improvement in PFS with 16 cycles of brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in BV-naive patients with high-risk relapsed/refractory classical Hodgkin lymphoma (r/r cHL). However, in real world, patients are rarely able to complete all 16 cycles of BV at full dose. We performed a multicenter retrospective study to assess the impact of cumulative dose on toxicity and 2-year PFS. Methods: Patients from 11 institutions across the US who had received at least one cycle of BV maintenance after ASCT for r/r cHL with one of these features were included: primary refractory disease (PRD), extra-nodal disease (END), or relapse < 12 months of diagnosis (RL<12). PFS was compared between the three cohorts based on a total cumulative dose of 28.8 mg/kg (1.8 mg/kg x 16 cycles): C1, those that received >75% (21.7 to 28.8 mg/kg) cumulative dose of BV, C2, those that received between 51% -75% (14.5 to 21.6 mg/kg) dose and C3, those that received ≤ 50% (≤ 14.4 mg/kg) dose. Results: Between July 2015-June 2019, 100 patients with a median age of 34 years (19-70) underwent ASCT for r/r cHL. At relapse, 44% had PRD, 47% had RL<12, 39% had END and 45% had received BV as initial (1%) or salvage (44%) therapy. 71% had CR before ASCT and 23% received >1 line of salvage (>1 SLT). There was no difference in baseline characteristics between the cohorts. Thirty-six patients were in C1, 27 in C2, and 37 in C3. Only 14% of patients received full cumulative dose of BV. The median number of cycles completed was 12. Fifty-seven patients discontinued early: 39 for toxicity, 7 for progression, 5 for patient preference, 2 for cost and 4 for other reasons. Six of the patients who stopped early for progression were in C3. Grade ≥3 adverse events for neuropathy, neutropenia, and infections were 16%, 7%, and 5% respectively. There was no difference in severity of neuropathy in patients who had received BV prior to ASCT (p=.37). The median follow up was 3.37 years (.4–6.35). The 2-year PFS was 85% for all subjects, 94% for C1, 84% for C2, and 72% for C3 (p=.079) (Table). Patients in C3 had worse PFS compared to C1 (p=.035); this difference remained significant after adjusting for five other factors. There was no difference in PFS between C1 and C2 (p=.29). Conclusions: The majority of patients discontinued BV maintenance early due to toxicity. 2-year PFS was robust regardless of cumulative dose of BV. We conclude that total cumulative dose of 28.8 mg/kg of BV maintenance is not necessary and 51%-75% of total BV dose may still attain a similar PFS advantage. [Table: see text]
35
Wagner, Charlotte Burton, Daniel Arthur Ermann, Kenneth M. Boucher, Adrienne Nedved, Ivana N. M. Micallef, Haris Hatic, Gaurav Goyal, et al. "Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?" Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 7514. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.7514.
Full textAbstract:
7514 Background: The AETHERA trial demonstrated improvement in PFS with 16 cycles of brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in BV-naive patients with high-risk relapsed/refractory classical Hodgkin lymphoma (r/r cHL). However, in real world, patients are rarely able to complete all 16 cycles of BV at full dose. We performed a multicenter retrospective study to assess the impact of cumulative dose on toxicity and 2-year PFS. Methods: Patients from 11 institutions across the US who had received at least one cycle of BV maintenance after ASCT for r/r cHL with one of these features were included: primary refractory disease (PRD), extra-nodal disease (END), or relapse < 12 months of diagnosis (RL<12). PFS was compared between the three cohorts based on a total cumulative dose of 28.8 mg/kg (1.8 mg/kg x 16 cycles): C1, those that received >75% (21.7 to 28.8 mg/kg) cumulative dose of BV, C2, those that received between 51% -75% (14.5 to 21.6 mg/kg) dose and C3, those that received ≤ 50% (≤ 14.4 mg/kg) dose. Results: Between July 2015-June 2019, 100 patients with a median age of 34 years (19-70) underwent ASCT for r/r cHL. At relapse, 44% had PRD, 47% had RL<12, 39% had END and 45% had received BV as initial (1%) or salvage (44%) therapy. 71% had CR before ASCT and 23% received >1 line of salvage (>1 SLT). There was no difference in baseline characteristics between the cohorts. Thirty-six patients were in C1, 27 in C2, and 37 in C3. Only 14% of patients received full cumulative dose of BV. The median number of cycles completed was 12. Fifty-seven patients discontinued early: 39 for toxicity, 7 for progression, 5 for patient preference, 2 for cost and 4 for other reasons. Six of the patients who stopped early for progression were in C3. Grade ≥3 adverse events for neuropathy, neutropenia, and infections were 16%, 7%, and 5% respectively. There was no difference in severity of neuropathy in patients who had received BV prior to ASCT (p=.37). The median follow up was 3.37 years (.4–6.35). The 2-year PFS was 85% for all subjects, 94% for C1, 84% for C2, and 72% for C3 (p=.079) (Table). Patients in C3 had worse PFS compared to C1 (p=.035); this difference remained significant after adjusting for five other factors. There was no difference in PFS between C1 and C2 (p=.29). Conclusions: The majority of patients discontinued BV maintenance early due to toxicity. 2-year PFS was robust regardless of cumulative dose of BV. We conclude that total cumulative dose of 28.8 mg/kg of BV maintenance is not necessary and 51%-75% of total BV dose may still attain a similar PFS advantage. [Table: see text]
36
Corici, Claudia, Zsófia Kohajda, Attila Kristóf, András Horváth, László Virág, Tamás Szél, Norbert Nagy, et al. "L-364,373 (R-L3) enantiomers have opposite modulating effects on IKs in mammalian ventricular myocytes." Canadian Journal of Physiology and Pharmacology 91, no. 8 (August 2013): 586–92. http://dx.doi.org/10.1139/cjpp-2012-0407.
Full textAbstract:
Activators of the slow delayed rectifier K+ current (IKs) have been suggested as promising tools for suppressing ventricular arrhythmias due to prolongation of repolarization. Recently, L-364,373 (R-L3) was nominated to activate IKs in myocytes from several species; however, in some studies, it failed to activate IKs. One later study suggested opposite modulating effects from the R-L3 enantiomers as a possible explanation for this discrepancy. Therefore, we analyzed the effect of the RL-3 enantiomers on IKs in ventricular mammalian myocytes, by applying standard microelectrode and whole-cell patch-clamp techniques at 37 °C. We synthesized 2 substances, ZS_1270B (right) and ZS_1271B (left), the 2 enantiomers of R-L3. In rabbit myocytes, ZS_1270B enhanced the IKs tail current by approximately 30%, whereas ZS_1271B reduced IKs tails by 45%. In guinea pig right ventricular preparations, ZS_1270B shortened APD90 (action potential duration measured at 90% repolarization) by 12%, whereas ZS_1271B lengthened it by approximately 15%. We concluded that R-L3 enantiomers in the same concentration range indeed have opposite modulating effects on IKs, which may explain why the racemic drug R-L3 previously failed to activate IKs. ZS_1270B is a potent IKs activator, therefore, this substance is appropriate to test whether IKs activators are ideal tools to suppress ventricular arrhythmias originating from prolongation of action potentials.
37
Subhashini, Lavanya, Jyoti Sarin, and Ravi Shankar. "Effectiveness Of Video Assisted Teaching On Danger signs in New born Of Mothers Of Preterm Baby In A Selected Hospital Of Kolar." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 09, no. 4 (December 15, 2019): 117–21. http://dx.doi.org/10.58739/jcbs/v09i4.7.
Full textAbstract:
Introduction: Preterm birth is defined as childbirth occurring at less than 37 completed weeks. Educational interventions for mothers are commonly viewed as an important strategy to promote their knowledge and practice of childcare skills. Aim: To assess and compare the effectiveness of Video Assisted Teaching on Danger signs in newbornof moth-ers of Preterm baby in both control and experimental group. Materials and Methods: Quasiexperimental research design with two group pretest posttest design was used for the study. The study was conducted in Neonatal Intensive Care Unit (NICU) of RL Jallapa Hospital and Re-search centre at Kolar. Total of 150 mothers, 75 each in experimental and control group were selected by pur-posive sampling technique. Results: The overall mean pre test knowledge score (5.62±2.8) in experimental group was significantly higher (t=2.53; p<.01) than that of pre test knowledge score (4.69±2.01) in control group. The overall mean post test knowledge score (15.71±1.26) in experimental group was significantly higher (t=0.14; p<.0001) than that of post test knowledge score (5.04±1.96) in control group. Conclusion: Video assisted teaching had enhanced the knowledge of mothers regarding danger signs of new-born. The study highlights the importance of educational support to mothers of preterm baby. Key words: Danger signs, Preterm baby, Video assisted teaching and Knowledge
38
LOPES, Célia Maria Condeixa de França, Jessica GALVAN, Ana Claudia Rodrigues CHIBINSKI, and Denise Stadler WAMBIER. "Fluoride release and surface roughness of a new glass ionomer cement: glass carbomer." Revista de Odontologia da UNESP 47, no. 1 (February 15, 2018): 1–6. http://dx.doi.org/10.1590/1807-2577.06717.
Full textAbstract:
Abstract Objective This study analyzed the fluoride release/recharge and surface roughness of glass carbomer compared to other encapsulated glass ionomer cements (GICs). Material and method The GICs tested were Glass Fill® (GC-GCP Dental), Riva Self Cure® (RS-SDI), Riva Light Cure® (RL-SDI), Equia Fil® (EF-GC Europe). The composite resin Luna® (LU-SDI) was used as control. Five samples of each material were prepared and kept in a humidifier for 24 hours (37 °C, 100% relative humidity). Fluoride release was measured in two times: before (T1: days 1, 2, 7, 14) and after topical application of fluoride (T2: days 15, 16, 21 and 28). The surface roughness was also measured in both times (T1: days 1 and 14; T2: days 15 and 28). All samples were submitted to a single topical application of acidulated fluoride phosphate (Fluor Care - FGM). Two-way ANOVA with repeated measures and Tukey's post-test (p <0.05) were used in the statistical analysis. Result Equia Fil presented the highest fluoride release in both evaluation periods, with a higher release in T1 (p <0.05). The other materials tested, including glass carbomer presented similar release in both periods (T1 and T2). Regarding surface roughness, no significant differences were observed in the interaction between the material × time factors (T1 and T2) (p=0.966). Conclusion The GICs tested presented fluoride release and recharge ability and showed no surface roughness increase by topical application of fluoride.
39
Lohiya, Ramprakash, Nipun Jindal, Vikas Bachhal, Sudhir Kumar Garg, and Sabyasachi Bhowmik. "Hoffa fracture: analysis of factors affecting the final outcome after treatment with partially threaded screws." International Journal of Research in Orthopaedics 3, no. 4 (June 23, 2017): 814. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20172879.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Coronal fractures of the femoral condyles are rare injuries.</p><p class="abstract"><strong>Methods:</strong> This retrospective case series included patients with coronal fractures of the femoral condyles managed operatively. The surgeries were performed by authors NJ, RL and VB. A total of 11 patients with Hoffa fracture were operated between May 2011 and July 2012.<strong></strong></p><p class="abstract"><strong>Results:</strong> We report the outcome of open reduction and internal fixation using partially threaded screws in 11 patients with Hoffa fracture. There were 10 male and 1 female patient operated at a mean age of 37 years. The average duration of follow up was 15.6 months. Fractures in all the patients united with a mean 115.45<sup>0</sup> range of flexion at knee at final review. The final outcome had a poor correlation with the shear angle of the fracture but fracture comminution and open nature of injury had a negative effect on the final outcome achieved. The number of screws used and the type of rehabilitation followed post operatively also had no bearing on the final range of motion achieved.</p><p class="abstract"><strong>Conclusions:</strong> Partially threaded screws offer consistently good results in coronal fractures of the femoral condyles and the outcome is dictated only by perioperative factors like comminution and open nature of injury.</p>
40
Waterhouse, Elizabeth. "Predictors of Early Seizures after Stroke." Epilepsy Currents 2, no. 3 (May 2002): 75–76. http://dx.doi.org/10.1111/j.1535-7597.2002.t01-1-00028.x.
Full textAbstract:
Prevalence and Predictors of Early Seizure and Status Epilepticus after First Stroke Labovitz DL, Allen Hauser W, Sacco RL Neurology 2001;57:200–206 Background Early seizure (ES) has been reported in 2 to 6% of strokes and is a predictor of recurrent seizures. Acute stroke has been reported to cause 22% of all cases of status epilepticus (SE) in adults. The determinants of ES and SE after stroke, however, are not well understood. Methods An incidence study was conducted to identify all cases of first stroke in adult residents of northern Manhattan. Cases of ES and SE within 7 days of stroke were identified through medical record review. Statistical analyses were performed by using univariate and multivariate logistic regression models. Results The cohort consisted of 904 patients; ES occurred in 37 (4.1%). The frequency of ES by stroke subtype and location was deep infarct in two (0.6%) of 356, lobar infarct in 20 (5.9%) of 341, deep intracerebral hemorrhage (ICH) in four (4.0%) of 101, lobar ICH in seven (14.3%) of 49, and subarachnoid hemorrhage in four (8.0%) of 50. SE occurred in 10 (1.1%) patients, representing 27.0% of patients with ES. Diabetes, hypertension, current smoking, alcohol use, age, gender, and race/ethnicity were not significant determinants of ES. In a subgroup of patients who had a National Institutes of Health (NIH) stroke scale (NIHSS) score recorded, NIHSS score was not an independent predictor of ES in multivariate analysis. After accounting for stroke severity, ES was not a predictor of 30-day case fatality. Conclusions Lesion location and stroke subtype are strong determinants of ES risk, even after adjusting for stroke severity. ES does not predict 30-day mortality. SE occurs in more than one fourth of patients with ES.
41
CHOUDRY, ABEERA, Amhreen Anwar, SUMAIRA KHAN, Rian Shukr, and HUMAIRA HAFEEZ. "INTRAUTERINE GROWTH RESTRICTION." Professional Medical Journal 16, no. 04 (December 10, 2009): 589–99. http://dx.doi.org/10.29309/tpmj/2009.16.04.2750.
Full textAbstract:
O b j e c t i v e : To compare fetal outcome in normal umbilical artery Doppler findings to abnormal umbilical artery Doppler findingsin pregnant women with fetal growth restriction.Main o u t c o m e m e a s u r e s : Umbilical artery Doppler studies, apgar score at 1 minute and apgarscore at 5 minutes after delivery.Study D e s i g n : Cross-sectional, comparative study. Setting: Department of Obstetrics and Gynaecology,Military Hospital and Combined Military Hospital, Rawalpindi. From Jan 2005 to Jan2007.Methods: Patients with fetal growth restriction between28 to 37 weeks of pregnancy were selected, in whom diagnosis was confirmed by ultrasonography. All patients were followed up with umbilicalartery Doppler studies. The study group consisted of 48 women (group I), where the umbilical artery waveform was compromised. The outcomein these was compared with an equal number of controls, where growth restricted fetuses had normal Doppler waveforms (group II). R e s u l t s:The mean age of patients in group I was 26.9 years and in group II was 28.6 years. Fetuses with abnormal umbilical artery Doppler findingshad higher incidence of maternal gestational hypertension and oligohydramnios. Rate of emergency cesarean section for fetal distress wasalso higher in this group. Growth restricted babies with abnormal umbilical artery Doppler waveforms had lower apgar scores. In babies withnormal Doppler studies, 91.6% had apgar score above 7 at 5 minutes after birth. In babies with raised Rl 78.1%, in babies with abscent enddiastolic flow 54.5% and in babies with Reversed end diastolic only 20% had apgar score above 7 at five minutes after birth. The differencewas statistically significant (P=0.001 (.Conclusion: Umbilical artery velocimetry can distinguish the group of growth restricted fetuses at riskof poor apgar. Growth restricted fetuses with normal Doppler studies are at a lower risk than those with abnormal Doppler findings in terms ofpoor apgar score.
42
Nasti, Guglielmo, Alessandro Ottaiano, Carmen Romano, Francesco Izzo, Paolo Delrio, Vittorio Albino, Pasqualina Giordano, et al. "FOLFIRI plus bevacizumab (B) as neoadjuvant treatment for potentially resectable colorectal cancer patients (pts) with liver metastasis: A phase II trial." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14130-e14130. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14130.
Full textAbstract:
e14130 Background: Irinotecan-based chemotherapy plus B was shown to be effective and safe in both first- and second-line treatment for metastatic colorectal cancer (mCRC) pts.We designed this trial to assess whether the combination of FOLFIRI + B given to untreated, potentially resectable mCRC pts was feasible and active. Methods: Phase II, single arm trial with 1-year progression-free rate (PFR) as primary end-point. A sample size of 39 pts was calculated to detect a 70% ± 12% 1-year PFR. The treatment was FOLFIRI q2w (irinotecan 180 mg/m2, leucovorin 200 mg/m2, 5FU 2400 mg/m2 iv in 46 hrs) plus B 5mg/kg q2w. Last cycle before surgery was without B. Potentially resectable, untreated mCRC pts, with liver as unique site of metastases, were eligible. Normal organ function and no contraindications to B were required. Pts were reevaluated for surgery after 6 cycles. PET-Scan were performed at baseline and at the second cycle. Results: Overall 39 pts were enrolled. Median age was 58 (range 30-75), male/female were 24/15. Twenty seven pts (69.2%; 95%CI 52.4% – 83.0%) were progression-free at 1-year. Thirty seven pts (94.9%) underwent surgery. One complete and 22 partial responses were observed (response rate 59.0%; 95% CI 42.1% – 74.4%); 5 pts had disease progression (4 resectable and 1 unresectable). Early PET-scan was assessed according PERCIST criteria [Wahl RL, J Nucl Med 2009] in 29 pts and showed metabolic response (SUV-max decrease > 30%) in 17 (58.6%; 95% CI: 38.9%- 76.5%).Severe toxicity includes grade 3 neutropenia (3 pts, 7.7%) and grade 3 diarrhea (1 pt, 2.6%). Other toxicities include grade 1-2 diarrhea (15.4%), grade 2 nausea (7.8%), grade 2 leucopenia (5.1%), grade 2 asthenia (5.1%), grade 1 anemia (2.6%), grade 2 thrombosis (2.6%). Overall, 16 pts out of 37 experienced surgical complications (43.2%; 95%CI 27.1% - 60.5%): biliary leak (11 pts, 29.7%), biliary fistula (1 pt, 2.7%), other complications (4 pts, 10.8%). All complications were reversible. No peri-operative bleeding was observed. Conclusions: The trial yielded its primary aim and shows that FOLFIRI plus B is feasible and active as neo-adjuvant treatment in patients with resectable liver metastases of CRC.
43
Ruble, Kathy, Lisa Carey, Juliana Pare-Blagoev, Kimberly Milla, Sydney Henegan, Katrina Cork, Clifton Thornton, and Lisa Jacobson. "Lessons from COVID-19, challenges of remote learning for childhood cancer survivors." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 10054. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.10054.
Full textAbstract:
10054 Background: More than half of childhood cancer survivors (survivors) will have neurocognitive deficits that impact schooling, most commonly reflecting attention and executive dysfunction. Schools are legally bound (IDEA, 2004) to support eligible students with Individualized Education Program (IEP) informed instruction and related services (e.g. assistive technology, speech-language, physical, or occupational therapy) to foster academic success. However, these service provision were not designed under the constraints of remote learning. The COVID19 shift to remote learning is likely to extend beyond the pandemic especially for medically fragile students. This quality improvement project describes challenges for survivors during remote learning and recently developed related patient education materials. Methods: Interviews with families were used to identify themes around challenges during remote learning, which informed development of a 29-question survey disseminated via flyer in local oncology clinics and social media posts by local childhood cancer organizations in Fall 2020. Results: The survey was completed by 67 parents describing their affected child (mean age= 8.6 years; 60% male; 78% White, 12% Black, 95% non-Hispanic). Most children (74%) had completed therapy (43% for leukemia, 18% for brain tumor; 39% other). The majority (86%) attended public school and 37% received special education or related services: speech-language (26%), occupational (23%), and physical (14%) therapies, and vision services (3%). Fully remote learning was reported for 73%, in-person 4%, and hybrid learning for 14%. The majority (57%) reported observing greater difficulty with attention and focus during RL, indicating difficulty occurred about half of the time during related services therapies, class and/or small group video instruction. Technology-related challenges included difficulty navigating online instruction/equipment (28%), reading difficulty (16%), and difficulty seeing materials/lack of vision supports (18%). Findings did not differ based on treatment or IEP status (p>0.50). Few (14%) reported their school team discussed assistive technology options for online learning. Parents indicated the most helpful supports for addressing challenges included speech-to-text tools, screen readers, and audio books. Parents reported their oncology team was helpful in making referrals to neuropsychology and therapies and completing documentation necessary to secure supports. Conclusions: Childhood cancer survivors, irrespective of diagnosis or IEP status, report challenges with remote learning. Families find a lack of information or special accommodations as roadblocks to success. Oncology providers were identified as valued resources, so educational materials ( https://tinyurl.com/nxbhj5or ) were developed for oncology teams to share with families.
44
Delmer, Alain, Stéphane Leprêtre, Bruno Cazin, Pierre Feugier, Olivier Tournilhac, Michel Leporrier, Brigitte Dreyfus, et al. "Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW." Blood 108, no. 11 (November 16, 2006): 2831. http://dx.doi.org/10.1182/blood.v108.11.2831.2831.
Full textAbstract:
Abstract New treatment approaches in CLL aim at lowering as much as possible the level of minimal residual disease (MRD) to prolong the duration of response and eventually overall survival. Such a goal should be achieved by combining chemotherapy and monoclonal antibodies. The present phase II study was designed to evaluate the efficacy and the safety of first line therapy with 3 courses of oral fludarabine and cyclophosphamide (FC : F 40 mg/m² and C 250 mg/m² D1 to D3 every 4 weeks) followed by consolidation treatment with alemtuzumab in previously untreated patients (pts) aged 65 to 70 years with Binet stages B and C CLL. Pts achieving complete response (CR) and partial response (PR) after FC were eligible for the second part of the study i.e. consolidation with alemtuzumab administered subcutaneously (SC) at the dose of 10 mg thrice a week for 8 weeks. CMV antigenemia was monitored every week and alemtuzumab was discontinued in pts with more than 3 positive nuclei. MRD was evaluated before and during alemtuzumab treatment using a highly sensitive 6 color flow cytometry technique. Since severe infectious toxicity has been reported by others with similar strategies, FC regimen was limited to 3 courses and the duration of alemtuzumab treatment to 8 weeks with stringent stopping rules for CMV in this trial targeting a population of elderly pts in first line treatment. From June 2004 to June 2006, 42 pts have been enrolled in the study of whom 37 are assessable so far for induction treatment with FC. CR was achieved in 11 pts (30%) and PR in 17 pts (46%) for an overall response rate of 76% (28 pts). FC regimen was discontinued in 5 pts (13.5%) and stable disease was observed in 3 pts (8%). All the responding pts but one (one woman with onset of breast cancer) proceeded to alemtuzumab consolidation after a 2 month rest period. Alemtuzumab therapy has been completed in 16 pts, discontinued in 5 pts because of CMV reactivation as defined above (none of them developed CMV disease) and is still on going in 6 pts. Blood MRD assessment by flow cytometry was centralized in one center (RL) and could be performed in 19 pts with a set of 14 pts having been tested sequentially before alemtuzumab, after 4 weeks and after 8 weeks of treatment. In most cases, there was an impressive decrease of MRD level following alemtuzumab therapy and residual tumor cells were no longer detected. Detailed results of MRD study will be presented at the meeting. In conclusion, 3 courses of FC yielded a high response rate in previously untreated elderly CLL patients and SC alemtuzumab consolidation could thereafter be administered safely in most of them, resulting in a striking reduction of blood MRD.
45
Zafani, Gabriella Cardana, Ingrid Pimentel Buosi, Shizumi Iseri Giraldelli, Talita Costa Barbosa, Amanda Oliva Spaziani, Juliana Aparecida da Silva, and Leonardo Faidiga. "A relação da polifarmácia e adesão medicamentosa com compensação ou não de doenças em idosos residentes com familiares, cônjuges ou sozinhos." ARCHIVES OF HEALTH INVESTIGATION 9, no. 5 (April 20, 2020): 410–13. http://dx.doi.org/10.21270/archi.v9i5.4846.
Full textAbstract:
A polifarmácia pode ser compreendida como o uso de múltiplos medicamentos simultaneamente. No Brasil, a prevalência de polifarmácia na população idosa varia entre 25 a 36%. Considerando a importância do tema, esse estudo visa analisar a relação polifarmácia e adesão de medicamentos de uso crônico com compensação ou não da patologia em idosos que residem sozinhos ou com familiares. O estudo foi realizado através de prontuários de uma Unidade Básica de Saúde. Há 545 idosos na área determinada para estudo, dos quais 114 foram analisados. Analisou-se: a idade, a (s) doença (s) que o paciente possui, uso de medicação específico para tal doença, se a doença encontra-se compensada ou descompensada e se o paciente reside sozinho, com o cônjuge ou familiares. Os resultados obtidos foram: 79% pacientes dos 114 estavam com suas patologias compensadas, 3% tinham uma delas descompensada e 18% estavam descompensados, conforme ilustrado no gráfico abaixo. 77,1% do total de pacientes possuem a patologia compensada e desses 54,5% residem com a família, entretanto, esse número também se manteve alto em relação a patologias descompensadas. Não pode se estabelecer uma relação direta entre a compensação e descompensação das patologias, talvez devido o valor limitado de participantes. Na literatura não há muitos estudos que relacionam a polifarmácia e adesão medicamentosa por idosos tornando-se necessário novos estudos. Ressalta-se que com o envelhecimento populacional e a política de acesso a medicamentos, a tendência é aumentar a utilização de medicamentos por idosos, que deve ser prioridade no planejamento do Sistema Único de Saúde.Descritores: Adesão à Medicação; Idoso; Serviços de Saúde para Idosos.ReferênciasRamos LR, Tavares NRL, Bertoldi AD, Farias MR, Oliveira MA, Luiza VL et al. Polifarmácia e polimorbidade em idosos no Brasil: um desafio em saúde pública. Rev Saúde Pública. 2016;50(Sup. 2):1s-13s.Souza DM, Souza LB, Lana GG, Souza SM, Aguilar NC, Silva DR. Uso inapropriado de medicamentos pelo idoso: polifarmácia e seus efeitos. Pensar Acadêmico Manhuaçu. 2018;16(2):166-78.Pereira KG, Peres MA, Iop D, Boing AC, Boing AF, Aziz M et al . Polifarmácia em idosos: um estudo de base populacional. Rev bras epidemiol. 2017;20(2):335-44.Cuentro VS, Modesto T, Andrade MA, Silva MVS. Prevalência e fatores associados à polifarmácia em idosos de um hospital público. Contexto & Saúde. 2016;16(30):28-35.Sales AS, Sales MGS, Casotti CA. Perfil farmacoterapêutico e fatores associados à polifarmácia entre idosos de Aiquara, Bahia, em 2014. Epidemiol Serv Saúde. 2017;26(1):121-32.Arruda DCJ, Eto FN, Velten APC, Morelato RL, Oliveira ERA. Fatores associados a não adesão medicamentosa entre idosos de um ambulatório filantrópico do Espírito Santo. Rev Bras Geriatr Gerontol. 2015;18(2):327-37.Cintra FA, Guariento ME, Miyasaki LA.. Adesão medicamentosa em idosos em seguimento ambulatorial. Ciênc saúde coletiva. 2010;15(3):3507-15.Lucchetti G, Granero AL, Pires SL, Gorzoni ML. Fatores associados à polifarmácia em idosos institucionalizados. Rev Bras Geriatr Gerontol. 2010;13(1):51-8.Magalhaes MS, Santos FS, Reis AMM. Fatores associados ao uso de medicamentos potencialmente inapropriados para idosos na alta hospitalar. Einstein (São Paulo). 2020;18:1-8.
46
Ryan, Maureen C., Brian Schimpf, Martha Anderson, Weiping Zeng, Kim Emmerton, Jamie Miyamoto, Heather Kostner, et al. "SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies." Blood 126, no. 23 (December 3, 2015): 594. http://dx.doi.org/10.1182/blood.v126.23.594.594.
Full textAbstract:
Abstract Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) have a poor prognosis. Despite measurable clinical activity seen with new targeted therapies, most r/r NHL patients do not achieve a complete or durable response suggesting there is room to improve upon existing clinical candidates. Here we describe SGN-CD19B, a new CD19-targeted antibody-drug conjugate (ADC), which demonstrates potent preclinical activity against B-cell malignancies. SGN-CD19B is composed of a humanized antibody (hBU12ec) conjugated to a DNA-cross linking pyrrolobenzodiazepine (PBD) dimer drug (SGD-1882) via a protease-cleavable linker. Fluorescence microscopy studies showed that SGN-CD19B is rapidly internalized and traffics to lysosomes within hours of binding to CD19-positive tumor cell lines. Following uptake, SGN-CD19B induces DNA damage as measured by phosphorylation of histone 2AX. This damage subsequently leads to G2-M cell cycle arrest, caspase-3/7 activation, formation of cleaved poly ADP-ribose polymerase and cell death. The antitumor activity of SGN-CD19B was evaluated in preclinical studies using lymphoma and leukemia cell lines. In vitro cytotoxicity studies showed that SGN-CD19B was highly active on a broad panel of CD19+ tumor cell lines with IC50 values ranging from 0.007 to12 ng/ml. SGN-CD19B displayed compelling anti-tumor activity in 4 separate xenograft models of B-cell malignancies including two models of diffuse large B-cell lymphoma (NHL-DLCL2 and RL), one model of Burkett's lymphoma (Ramos) and one model of B-cell acute lymphoblastic leukemia (B-ALL; Nalm-6). Amongst the NHL xenograft models, SGN-CD19B induced significant, dose-dependent tumor growth delay and survival benefit at ≥100 mcg/kg. At 300 mcg/kg, 100% of treated mice achieved complete and durable tumor regressions in 3 of 3 lymphoma models tested. In a disseminated model of B-ALL, a significant dose-dependent increase in survival was observed in mice treated with ≥10 mcg/kg of SGN-CD19B. At 100 mcg/kg, 10/10 mice survived for >115 days while the maximal survival for untreated and control groups was ≤37 days. The ability of SGN-CD19B to deplete normal B-cells was examined in conjunction with single-dose toxicology studies in monkeys. SGN-CD19B was tolerated up to 250 mcg/kg without severe toxicity. Reductions in peripheral CD20+ B-lymphocytes were observed at dose levels as low as 10 mcg/kg and higher. The magnitude and duration of B cell depletion was dose-dependent. CD20+ B-lymphocytes were also depleted from lymphoid tissues, which showed minimal to marked, dose-dependent decreases in the number and size of lymphoid follicle germinal centers at doses ≥30 mcg/kg. Normal lymphoid architecture was restored within 16 weeks and circulating CD20+ B-lymphocytes returned to normal levels within 8-12 weeks of dosing. Together, these data demonstrate that SGN-CD19B exhibits antitumor activity against a broad panel of CD19+ B-cell malignancies and causes durable remissions in preclinical models of NHL and B-ALL. SGN-CD19B is pharmacodynamically active in cynomolgus monkeys, resulting in 100% depletion of CD20+ B-lymphocytes at well-tolerated doses. Clinical trials are planned to further evaluate SGN-CD19B in r/r NHL. Disclosures Ryan: Seattle Genetics, Inc.: Employment. Schimpf:Seattle Genetics, Inc.: Employment. Anderson:Seattle Genetics,Inc: Employment. Zeng:Seattle Genetics, Inc: Employment. Emmerton:Seattle Genetics, Inc.: Employment. Miyamoto:Seattle Genetics, Inc.: Employment. Kostner:Seattle Genetics, Inc.: Employment. Yu:Seattle Genetics, Inc.: Employment. Van Epps:Seattle Genetics, Inc.: Employment. Tatalick:Seattle Genetics, Inc.: Employment. Benjamin:Seattle Genetics, Inc: Employment.
47
Prieto-Peña, D., F. Genre, S. Remuzgo Martinez, V. Pulito-Cueto, B. Atienza-Mateo, B. Sevilla, J. Llorca, et al. "AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IgA VASCULITIS AND IgA NEPHROPATHY?" Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1203–4. http://dx.doi.org/10.1136/annrheumdis-2022-eular.425.
Full textAbstract:
BackgroundIgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions [1, 2], that share pathogenic mechanisms [1], in which B-lymphocytes are described as key cells implicated in these processes. BAFF, APRIL and BAFF-R are cytokines implicated in the development of B-lymphocytes [3, 4] and in autoimmune processes [5, 6]. In this regard, an influence of BAFF, APRIL and BAFFR polymorphisms was observed on several immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion variant for inflammatory conditions [7, 8].ObjectivesTo determine whether BAFF, APRIL and BAFFR could be used as differential biomarkers between IgAV and IgAN.MethodsBAFF rs374039502 (which colocalizes with BAFF GCTGT>A), two tag variants within APRIL (rs11552708 and rs6608) and two tag variants within BAFFR (rs7290134 and rs77874543) were genotyped in 394 Caucasian IgAV patients, 95 patients with IgAN and 832 matched healthy controls.ResultsSimilar genotype and allele frequencies were observed in the whole cohort of patients with IgAV when compared to those with IgAN when BAFF, APRIL and BAFFR variants were analyzed independently (Table 1). In accordance with that, no BAFF, APRIL and BAFFR genotype or allele differences were detected between IgAV patients who developed nephritis and patients with IgAN (Table 1). Additionally, no statistically significant differences were observed between the whole cohort of patients with IgAV and healthy controls as well as between patients with IgAN and healthy controls when each when BAFF, APRIL and BAFFR genetic variant was also analyzed independently (Table 1). Similar results were disclosed when haplotype frequencies of APRIL and BAFFR were compared between the different comparative groups above mentioned (data not shown).Table 1.Genotype and allele frequencies of BAFF, APRIL and BAFFR in the whole cohort of patients with IgAV, patients with IgAV who developed nephritis, patients with IgAN and healthy controls.PolymorphismChangeData setGenotypes, % (n)Alleles, % (n)1/21/11/22/212BAFF rs374039502T/AIgAV92.1 (363)7.9 (31)0.096.1 (757)3.9 (31)IgAV with nephritis90.1 (128)9.9 (14)0.095.1 (270)4.9 (14)IgAN91.6 (87)8.4 (8)0.095.8 (182)4.2 (8)Controls91.8 (764)7.8 (65)0.4 (3)95.7 (1593)4.3 (71)APRIL rs11552708G/AIgAV78.7 (310)20.1 (79)1.3 (5)88.7 (699)11.3 (89)IgAV with nephritis81.1 (116)18.9 (27)0.090.6 (259)9.4 (27)IgAN75.8 (72)23.2 (22)1.1 (1)87.4 (166)12.6 (24)Controls78.7 (655)19.7 (164)1.6 (13)88.6 (1474)11.4 (190)APRIL rs6608C/TIgAV72.6 (286)25.4 (100)2.0 (8)85.3 (672)14.7 (116)IgAV with nephritis75.5 (108)23.1 (33)1.4 (2)87.1 (249)12.9 (37)IgAN65.3 (62)30.5 (29)4.2 (4)80.5 (153)19.5 (37)Controls71.0 (591)26.6 (221)2.4 (20)84.3 (1403)15.7 (261)BAFFR rs7290134A/GIgAV58.9 (232)35.5 (140)5.6 (22)76.6 (604)23.4 (184)IgAV with nephritis60.1 (86)32.2 (46)7.7 (11)76.2 (218)23.8 (68)IgAN57.9 (55)38.9 (37)3.2 (3)77.4 (147)22.6 (43)Controls58.7 (488)35.1 (292)6.3 (52)76.2 (1268)23.8 (396)BAFFR rs77874543G/CIgAV83.2 (328)15.5 (61)1.3 (5)91.0 (717)9.0 (71)IgAV with nephritis83.1 (118)16.9 (24)0.091.5 (260)8.5 (24)IgAN86.3 (82)13.7 (13)0.093.2 (167)6.8 (13)Controls83.7 (696)16.0 (133)0.4 (3)91.6 (1525)8.4 (139)IgAV: IgA vasculitis; IgAN: IgA nephropathy.ConclusionOur results reveal a similar BAFF, APRIL and BAFFR genetic distribution in IgAV and IgAN, suggesting that these genes could not be used as differential biomarkers between these pathologies.References[1]N Engl J Med 2013;368:2402-14;[2]Am J Kidney Dis 1988;12:373-7;[3]J Exp Med 1999;189:1747-56;[4]Nat Genet 2005;37:793-4;[5]Arthritis Res Ther 2018;20:158;[6]Arthritis Res Ther 2020;22:157;[7]Engl J Med 2017;376:1615-26;[8]Sci Rep 2018;8:8195.AcknowledgementsThis study was supported by the European Regional Development Fund (ERDF) and “Fondo de Investigaciones Sanitarias” (grant PI18/00042 and PI21/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by ERDF [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; RL-M is a recipient of a Miguel Servet type II programme fellowship from the ISCIII, co-funded by ESF `Investing in your future´ [grant number CPII21/00004].Disclosure of InterestsDiana Prieto-Peña: None declared, Fernanda Genre: None declared, Sara Remuzgo Martinez: None declared, Verónica Pulito-Cueto: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda Fillloy: None declared, J. Narváez: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Antonio Fernandez-Nebro: None declared, Gisela Díaz-Cordoves: None declared, Secundino Cigarrán: None declared, Jesús Calviño: None declared, Carmen Cobelo: None declared, Diego de Argila: None declared, Esther F. Vicente-Rabaneda: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galíndez-Agirregoikoa: None declared, Oreste Gualillo: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Miguel A González-Gay Speakers bureau: Abbvie, MSD, Jansen, and Roche, Grant/research support from: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD and GSK, Raquel López-Mejías: None declared
48
Gonzalez Gomez, C. A., M. Cosatti, V. V. Castro Coello, M. Haye, Y. Tissera, A. A. Reyes, J. A. Albiero, et al. "AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1668–69. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1021.
Full textAbstract:
BackgroundPersistent symptoms after acute COVID have been described previously. Main symptoms reported are fatigue, arthralgias, myalgias and mental sickness. Definition and methods vary widely.1ObjectivesTo asses prevalence and related factors to long COVID in a retrospective cohort of patients with rheumatic diseases from Argentina.MethodsA total of 1915 patients were registered from August 18th, 2020 to July 29th, 2021. Patients > 18 years old, with rheumatic disease and confirmed infection by SARS-CoV-2 (antigen or RT-PCR) were included. Those dead, with unknown outcome, wrong date or missing data were excluded. Demographic data, comorbidities, rheumatic disease, and characteristics of SARS-CoV-2 infection were recorded.Long COVID was defined according to NICE guidelines (persistent symptoms for more than 4 weeks, without alternative diagnosis). Long COVID symptoms were defined by rheumatologist. Severity of infection was classified according to WHO ordinal scale.We used descriptive statistics, univariate model (Student’s test, chi square test, ANOVA) and multivariate logistic regression analysis.Results230 (12%) had long COVID. Median age was 51 (IQR 40-61]) years, 82% were females, 51% were not caucasian. Median of education was 13.3 years (IQR 12 – 16), 79 % had private health insurance and 55 % were employed. Nearly half (n=762, 46%) had comorbidities, the most prevalent was hypertension (n=396, 24%).The most frequent rheumatic diseases were rheumatoid arthritis (n=719, 42%) and systemic lupus erythematosus (n=280, 16 %). Most were in low activity/remission (79%), used Conventional DMARD (n=773 patients, 45%) and steroids (n=588, 34%) at low dose (n=415, 71%).Main laboratory findings were abnormal D-dimer (n=94, 28%) and leukopenia (n=93, 26%). Most patients had a WHO ordinal scale < 5 (n=1472, 86%). Median of hospitalization at intensive care unit (ICU) was 8 days [IQR 5, 13]. Treatment for SARS-CoV-2 infection (steroids, anticoagulation, azithromycin, convalescent plasma) was used in 461 (27%) patients.Most of long COVID (n= 152, 69%) reported 1 symptom, the most frequent was fatigue (n= 55, 22%). Figure 1.Univariate analysis is presented in Table 1. In multivariate logistic regression analysis non-caucasian ethnicity OR 1.44 (1.07-1.95), years of education OR 1.05 (1-1.09), treatment with cyclophosphamide OR 11.35 (1.56-112.97), symptoms of COVID – 19 OR 13.26 (2.75-242.08), severity scale WHO ≥ 5 OR 2.46 (1.68-3.57), and ICU hospitalization days OR 1.09 (1.05-1.14) were factors associated to long COVID.Table 1.Univariate analysis of long COVID syndrome in SAR – COVID registryVariableAcute COVID n=1486Long COVID n=221P valueAge, years, median [IQR]51 [40, 60]54 [42, 62]0.032Caucasian, n (%)744 (48)132 (53)0.227Female sex, n (%)1242 (80)215 (86)0.066Education, years, median [IQR]12 [10, 17]13 [12, 16]-Private health insurance, n (%)1161 (79)181 (82)0.325Smoking, n (%)381 (25)71 (29)0.224Comorbidities, n (%)650 (45)108 (52)0.066Dyslipidemia, n (%)173 (12)39 (19)0.008Hypertension, n (%)332 (23)60 (29)0.053Low activity/remission disease, n (%)1140 (80)179 (77)1Rheumatoid arthritis, n (%)623 (42)96 (42)1Systemic lupus erythematosus, n (%)243 (16)37 (16)0.996DMARD, n (%)664 (45)109 (47)0.486Cyclophosphamide, n (%)3 (0.2)3 (1)0.035Rituximab, n (%)19 (1)9 (34)0.008Lymphocyte66 (23)19 (30)0.011<1.500 / mm3, n (%)Ferritin > 2000 ng/ml, n (%)32 (11)16 (25)0.011ICU hospitalization, days,7 [4, 10]10 [8, 24]<0.001median [IQR]Treatment for COVID-19, n (%)394 (27)91 (41)<0.001ConclusionPrevalence of long COVID was 12%. Non-caucasian ethnicity, higher education, treatment with cyclophosphamide, symptoms of COVID – 19, severe disease and ICU hospitalization days were related to long COVID.References[1]Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract.Disclosure of InterestsNone declared
49
Adkar-Purushothama, C. R., H. Nagaraja, M. Y. Sreenivasa, and T. Sano. "First Report of Coleus blumei viroid Infecting Coleus in India." Plant Disease 97, no. 1 (January 2013): 149. http://dx.doi.org/10.1094/pdis-08-12-0715-pdn.
Full textAbstract:
Members of the genus Coleviroid (Coleus blumei viroid [CbVd]), family Pospiviroidae have been reported to infect Coleus (Solenostemon sp.). CbVd-1 was first reported from Brazil, CbVd-2, -3, and -4 were first reported from Germany, whereas CbVd-5 and -6 were recently identified in China (2). In India, Coleus is extensively cultivated as an ornamental plant in home gardens. In March to June 2012, Coleus leaf samples with irregular chlorotic spots/patches were collected from home gardens of two different districts of Karnataka (Kodagu and Mysore districts), India, suspecting the presence of Coleus blumei viroids (CbVd 1 to 6). Low molecular weight RNAs were extracted using 2% CTAB buffer containing 1.4 M NaCl, 20 mM EDTA, pH 8.0 and 100 mM Tris-Cl, pH 8.0 (1). Viroid-like RNA was enriched by fractionation 2M LiCl soluble nucleic acids (4). A DNA fragment with the expected size of CbVd-1 was detected in 10 (including both districts) of 14 analyzed (incident rate of 71%) from reverse transcription (RT)-PCR assay using Coleviroid specific primers (forward 5′-TGGATCCAGCGCTGCAACGGAATCCA-3′ and reverse 5′-TTGGATCCGCCAGGGAACCCAGGTAAG-3′). RT was performed at 37°C for 60 min in 25 μl reaction mix containing 5 μl RNA extracts, 1 μl reverse primer, 1× first strand buffer, 10 mM dNTPs, and 200U M-MuLV-RT (Invitrogen, USA). For PCR, 2 μl RT was mixed in 25 μl PCR mix containing 0.2 μM each forward and reverse primers and 2U LA Taq (Takara-Bio, Japan) according to the manufacturer's instruction. PCR parameter was one cycle at 94°C for 2 min, 35 cycles at 94°C for 45 s, 53°C for 30 s, and 72°C for 60 s, followed by final extension at 72°C for 10 min (4). Sequence analysis of cloned amplicons detected CbVd-1 in India. To confirm the sequence of the primer regions, an additional set of tail-tail primers were designed, CbVd1-136F (5′-CTTCGTGGAACGGCTCCGCG-3′) and CbVd1-136Rev (5′-GAAGAAGCCGAAGCAACTCTC-3′) and were used for RT-PCR. Amplified products were cloned, sequenced and compared with previously obtained data. Further, the presences of CbVd-1 in Coleus samples was confirmed by a RNA gel blot assay using digoxigenin-labeled CbVd-1 cRNA probe (3). Alignment of 19 sequences obtained from four representative Coleus samples found the presence of two sequence variants of CbVd-1, namely Ind-1 (GenBank Accession No. AB740017) and Ind-2 (AB740018). Ind-1 was found to differ from Ind-2 by two nucleotide substitutions at position 40 (C to T) and 211 (T to C). BLAST analysis of Ind-1 showed 100% sequence similarity with CbVd-1 isolates from China (DQ178399) and South Korea (EU 410620), whereas Ind-2 was 99% identical to these two Chinese and Koreans isolates. Furthermore, 97% and 96% sequence identity with CbVd 1-RL RNA (Accession no. X95366) was observed for Ind-1 and Ind-2, respectively. Isolates from India were 88% similar with Coleus blumei viroid 1-RG (X95291). To the best of our knowledge, this is the first molecular evidence for the presence of CbVd-1 infecting Coleus in India. Coleus harbors various viroid species and CbVd-1, reported widely, can transmit efficiently through seed and also could infect the other herbaceous plants (3). This report from India will contribute further understanding of a potential risk of Coleus viroids in ornamental species. References: (1) J. J. Doyle and J. L. Doyle. Phytochem. Bull. 19:11, 1987. (2) F. H. Fu et al. Plant Dis. 95:494, 2011. (3) Ishiguro et al. Ann. Phytopathol. Soc. Jpn. 62:84, 1996. (4) S.-F. Li et al., Plant Pathol. 55:565, 2006.
50
Ramos, Julia, Melissa Rosenstein, and Andrew Leavitt. "Phlebitis after Parenteral Iron Sucrose Administration in Postpartum Women." Blood 132, Supplement 1 (November 29, 2018): 1052. http://dx.doi.org/10.1182/blood-2018-99-113182.
Full textAbstract:
Abstract Introduction: Multiple studies in industrialized countries indicate that postpartum anemia affects 20-50% of patients immediately after delivery (Barroso F et al Eur J Obstet Gynecol Reprod Biol 2011; Bergmann RL et al Eur J Obstet Gynecol Reprod Biol 2010; Urquizu IBX et al Med Clin (Barc) 2016). A growing body of literature suggests that intravenous (IV) iron improves time to anemia recovery in postpartum patients (Breymann C et al. Int J Gynaecol Obstet. 2008; Seid MH et al, Am J Obstet Gynecol 2008). We therefore developed recommendations for the use of IV iron on our Labor and Delivery (L&D) service to treat postpartum anemia. Three months after initiation of the IV iron recommendations, we performed an audit to assess its use. Methods: The UCSF pharmacy identified medical record numbers for obstetrical patients given IV iron sucrose 5/1/17 - 10/31/17, which spans 3 months pre-release of the IV iron protocol through the first 3 months after protocol release. Seventy-one patients were identified and their charts were individually reviewed to determine the dose and number of IV iron infusions received, interval between infusions when more than one infusion was given, the IV location for each infusion, and whether phlebitis was reported. Phlebitis was considered to have occurred if a physician or nursing note indicated that the patient had pain, swelling or erythema in an arm correlating to documented site of IV iron infusion. This study was conducted under UCSF Institutional Review Board approval number 17-22831. Results: Patients received 100 mg, 200 mg, or 300 mg of iron sucrose per infusion. Each infusion was administered over 30-90 minutes and patients received 1, 2, or 3 IV iron infusions. Venofer® is the only IV iron sucrose product received by patients in this study. The overall incidence of phlebitis was 9.9% (7 of 71 patients), higher than expected based on the previously published safety data and the published experience using IV iron sucrose in the postpartum setting (Breymann C et al. Eur J Clin Invest. 2000; Westad S et al. Acta Obstet Gynecol Scand. 2008). In addition, we found an increase in phlebitis incidence with increasing number of IV infusions: phlebitis was seen in 2 of 18 (11%) patients who received 2 iron infusions on consecutive days via a single IV site, while patients who received 300 mg iron sucrose on 3 consecutive days (5 out of 16 patients; Table 1) had a 31% incidence of phlebitis. Importantly, the phlebitis incidence was 50% for the 10 patients who received 3 infusions of 300 mg iron sucrose at a single IV site. Interestingly, in 6 patients who received 3 infusions of 300 mg iron sucrose on 3 consecutive days but had their peripheral IV re-sited between infusions, none developed phlebitis. No phlebitis was reported in 37 patients who received a single infusion of iron sucrose (100 - 300 mg dose range). Of the 7 phlebitis cases, 3 patients were readmitted to the hospital for evaluation and treatment. Three patients returned to our OB clinic or to L&D Triage for evaluation. One patient communicated her symptoms by telephone encounter. Discussion. IV iron safety analyses have historically focused on dose limitations and the risk for infusion reaction and anaphylaxis. We identified an increasing incidence of post-infusion phlebitis with increasing number of infusions of daily iron sucrose in patients admitted to our L&D service, an adverse event not previously highlighted in published safety literature for iron sucrose. We found the phlebitis events to be clinically significant for the patient, and to result in increased healthcare utilization post-infusion. It is our opinion that this adverse effect deserves attention because of the patient discomfort, inconvenience, and increased healthcare resource utilization. Physicians treating patients for iron-deficiency anemia, including hospitalists, hematologist, and OB-Gyn providers, should be aware of post-infusion phlebitis as a possible complication of iron sucrose therapy. Based on our findings, we recommend against daily IV iron sucrose infusions through a single peripheral venous access site. In addition, other formulations that allow for complete iron replacement in a single infusion session offer a convenience advantage to doctor and patient and may minimize the risk of phlebitis we observed with serial daily iron infusions. Disclosures No relevant conflicts of interest to declare.